Stockwinners Market Radar for May 10, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:15 EDT Cathie Wood's ARK Investment bought 419.6K shares of Velo3D today

19:07 EDT Kinetik intends to revise overall guidance upwards during Q2 - "On February 23, 2022, Kinetik provided 2022 Guidance, including full year 2022 Pro Forma Adjusted EBITDA of $770 million to $810 million and capital expenditures of $125 million to $150 million, including $55 million related to integration," the company said. "Based on our current forecast, Kinetik intends to revise upwards its overall guidance during the second quarter and will provide a market update on or before second quarter 2022 results. Kinetik also expects to undertake a comprehensive refinancing of its legacy indebtedness during the second quarter."

18:18 EDT Cameco increases ownership stake in Cigar Lake uranium mine - Cameco and Orano Canada have reached agreement with Idemitsu Canada Resources Ltd. to acquire Idemitsu's 7.875% participating interest in the Cigar Lake Joint Venture. Upon closing, Cameco's ownership stake in the Cigar Lake uranium mine in northern Saskatchewan will increase by 4.522 percentage points to 54.547%, while Orano's share will rise by 3.353 percentage points to 40.453%. TEPCO Resources Inc. retains the remaining 5% interest in the property. "As the world's largest high-grade uranium mine, Cigar Lake is quite simply one of the best and most prolific uranium producing assets on the planet," said Cameco president and CEO Tim Gitzel. "Cameco is very pleased to increase our ownership stake in this outstanding tier-one operation. As the operator of Cigar Lake since 2002, it's an asset we know incredibly well. It's a proven, permitted and fully licenced mine in a safe and stable jurisdiction that operates with the tremendous participation and support of our neighbouring Indigenous partner communities." Cameco's purchase cost to acquire its respective share of Idemitsu's interest in Cigar Lake is approximately C$107M, subject to customary closing adjustments. The acquisition is subject to certain regulatory approvals and other standard closing conditions. The transaction is expected to close in the second quarter of 2022.

18:06 EDT Franklin Resources reports preliminary AUM $1.456T as of April 30 - Compared to $1.476T at March 31. This month's decrease in AUM primarily reflected the negative impact of markets and long-term net outflows, partially offset by the April 1st acquisition of Lexington Partners.

17:38 EDT China's Lufax 'actively exploring possible' resolution to HFCAA issue with SEC - Lufax Holding provides an update on its status under the Holding Foreign Companies Accountable Act in a regulatory filing the company said "the HFCAA. On May 9, the U.S. Securities and Exchange Commission provisionally named the Company as a Commission-Identified Issuer under the HFCAA, following the Company's filing of its annual report on Form 20-F for the fiscal year ended December 31. The Company understands the SEC made this identification pursuant to the HFCAA and its implementation rules, and this indicates that the SEC has determined that the Company used an auditor whose working papers cannot be inspected or investigated completely by the Public Company Accounting Oversight Board of the United States to issue the audit opinion for the Company's financial statements included in the 2021 Form 20-F. In accordance with the HFCAA, if the SEC determines that the Company filed audit reports issued by a registered public accounting firm that has not been subject to inspection for the PCAOB for three consecutive years, the SEC will prohibit the ordinary shares and American depositary shares of the Company from being traded on a national securities exchange or in the over-the-counter trading market in the United States. The Company's ADSs, each two ADSs representing one ordinary share, are listed on the New York Stock Exchange. The Company has been actively exploring possible solutions. The Company will continue to comply with applicable laws and regulations in the United States and strive to maintain its listing status on the New York Stock Exchange."

17:26 EDT Nicholas Financial appoints Michael Rost as interim CEO - Nicholas Financial announced the appointment of Michael Rost as interim CEO of the Company effective May 9. Rost has worked at the Company for more than 20 years, most recently in the position of Vice President of Branch Operations. The Board appointed Rost in connection with the resignation by Douglas Marohn from his position as the Company's President and CEO.

17:12 EDT Cardlytics announces $40M stock repurchase program - Cardlytics "announced that its Board of Directors has approved the repurchase of up to an aggregate of $40.0 million of its Common Stock. The repurchase program is expected to continue through the end of the current fiscal year unless extended or shortened by the Board of Directors."

17:07 EDT Palantir awarded $30M contract modification from Defense Logistics Agency - Palantir USG Inc., Palo Alto, California, was awarded a $30,000,000 firm-fixed-price modification to previously awarded contract FA8806-21-C-0010 for a Data-as-a-Service Platform. The contract modification provides for the exercise of an option for additional term software licenses, cloud hosting, enablement services, support and training for each platform solution under the basic contract. Work will be performed in El Segundo, California; Palo Alto, California; Washington, D.C.; and New York, New York, and is expected to be completed by Nov. 30, 2022. Fiscal 2022 operations and maintenance funds in the amount of $16,895,000; and fiscal 2022 research, development, test and evaluation funds in the amount of $2,000,000 are being obligated at the time of award. The total cumulative face value of the contract is $121,500,000.

17:02 EDT Unity Software drops 35% to $31.40 after cutting FY22 revenue outlook

16:53 EDT Global Cord Blood receives copy of Blue Ocean petition - Global Cord Blood announced that the Company has received a copy of a petition that was filed with the Grand Court of the Cayman Islands by Blue Ocean Structure Investment Company. The Company is taking legal advice in response to Blue Ocean's petition and will make further announcements as appropriate in due course.

16:50 EDT Arcellx doses first patient in ACLX-001 Phase 1 clinical study of ARC-SparX - Arcellx announced that the first patient has been dosed in its open-label, multicenter ACLX-001 Phase 1 clinical trial to evaluate the company's novel ARC-SparX program in patients with relapsed or refractory multiple myeloma. ARC-SparX is a universal cell therapy platform comprised of SparX proteins engineered to target BCMA on myeloma cells together with ARC-T cells that are dosed separately and are engineered to activate only when engaged with a SparX protein bound to a myeloma cell. Both the ARC-T cells and SparX proteins utilize the company's proprietary novel synthetic binding scaffold called the D-Domain. Initial data from the ACLX-001 Phase 1 study is expected in 2023.

16:48 EDT HSGS-Ameresco JV awarded $7.9M project - HSGS-Ameresco, a joint venture certified as a Service-Disabled Veteran Owned Small Business by the Small Business Administration and the Department of Veterans Affairs, announced that it has been awarded a $7.9M contract to design and construct a 1.5 MW ground mount solar photovoltaic system for the U.S. Army at its Tooele Army Depot located in Tooele, Utah.

16:47 EDT AN2 Therapeutics expects cash to fund operations through mid-2024 - Cash, cash equivalents and short-term investments totaled $118.4 million on March 31, 2022. The Company expects that current cash, cash equivalents and investments, including net proceeds from the underwriters' over-allotment option exercised in April, will be sufficient to fund its operating expenses through mid-2024.

16:43 EDT Olo appoints Diego Panama as chief revenue officer - Olo Inc. (OLO) announced the appointment of Diego Panama to Chief Revenue Officer, effective July 5, 2022, and the retirement of Marty Hahnfeld, Chief Customer Officer, effective June 30, 2022. Panama will assume the roles and responsibilities of Hahnfeld under the new title of Chief Revenue Officer. Panama joins Olo from LiveRamp (RAMP), where he most recently served as its Chief Commercial Officer.

16:41 EDT Citizens announces new $8M share repurchase program - Citizens announced that its Board of Directors has unanimously authorized a new share repurchase program under which the company may repurchase up to $8M of its outstanding shares of Class A common stock.

16:40 EDT Canoo sees Q2 CapEx $85M-$105M - Sees Q2 operating expenses $95M-$115M.

16:38 EDT Virtus Investment reports preliminary AUM $170.9B as of April 30 - In addition, the company provided services to $3.2B of other fee-earning assets, which are not included in assets under management.

16:34 EDT Turning Point Therapeutics expects cash to fund operations into H2 of 2024 - Cash, cash equivalents and marketable securities as of March 31, 2022 totaled $918.2 million, reflecting a net decrease of approximately $63 million from December 31, 2021. Turning Point projects its cash position is sufficient to fund current operations through the first half of 2024.

16:33 EDT FMC Corporation obtains pre-suit injunction in China for patent infringement - FMC Corporation announced the Ningbo Intermediate People's Court in Zhejiang Province, China, granted FMC Agro Singapore Pte. Ltd a pre-suit preliminary injunction to stop infringement of a chlorantraniliprole patent. Chlorantraniliprole is FMC's leading insecticide ingredient branded as Rynaxypyr active. The pre-suit preliminary injunction restrains Zhejiang Yongtai Technology Co. Ltd. from engaging in any activity of offering to sell chlorantraniliprole until FMC's patent expires, including by doing so at trade fairs. "We are pleased with the Court's decision, which reflects its understanding of the urgency of this matter and its impact on the crop protection market in China," said Michael Reilly, FMC executive vice president, general counsel and secretary. "The principles decided by the Court are also significant for future infringement actions, as being one of very few cases anywhere in China where a trial court has granted pre-suit injunctive relief under the China Patent Law and standards outlined by the Chinese Supreme Court. The Ningbo Intermediate People's Court determined that Yongtai Technology's infringing acts violated the China Patent Law and created a need for urgent relief to protect FMC's patent rights."

16:31 EDT Coinbase: 2022 outlook 'largely unchanged' - The company said: "We continue to expect that during a prolonged and stressful scenario for our business, we will aim to manage our 2022 potential Adjusted EBITDA losses to approximately $500 million on a full-year basis." Sees annual average MTUs 5M-15M, with "strong" subscription and services growth and transaction expenses in the low 20%s.

16:30 EDT Coinbase sees Q2 MTUs, Trading Volume lower vs. Q1 - Sees subscription and services revenue will be similar to modestly lower in Q2 compared to Q1. Sees e transaction expenses to be in the low 20s as a percent of net revenue.

16:27 EDT Vuzix CEO says Q2 outlook 'quite positive' - "Our outlook for 2022 remains quite positive despite continuing and challenging supply chain, geopolitical, and economic uncertainties. Adoption of smart glasses over the course of the year is expected to again accelerate with existing customer repeat orders and in some cases we anticipate significant new opportunities from new programs," said CEO Paul Travers. "Over the last year plus, we have invested in our core technology and OEM component platforms. The significant improvements we have made in our waveguide manufacturing quality and performance along with our ability to more easily manufacture in volume at competitive price points, is opening new doors with consumer OEM customers. In addition, with the expiration of our non-compete related to the defense markets occurring this June, we will be able to fully engage with any US or allied defense and homeland defense forces globally," concluded Travers.

16:26 EDT Rackspace Technology says evaluating strategic alternatives - Kevin Jones, CEO of Rackspace Technology, said: "Rackspace Technology recently completed an in-depth strategic review of our company. As we completed this strategic review, and also based on inbound interest for one of our businesses, we concluded that a sum of the parts valuation of Rackspace Technology could be greater than our current enterprise value. This is in part driven by the attractive growth profile of Public Cloud. Accordingly, we are evaluating strategic alternatives and options. We will provide further information as appropriate in light of developments."

16:21 EDT Danimer Scientific sees FY22 adjusted EBITDA ($45M)-($35M) - The company said: "The Company expects its Kentucky facility to have a favorable year-over-year impact and to turn profitable as it increases its PHA-based revenues and drives operational efficiencies. The improved profitability from PHA-based revenues is expected to be more than offset by lower PLA-based revenue, a full year of prior SG&A and R&D investments to support growth, as well as a full year of consolidated costs from Danimer Catalytic Technologies acquired in August 2021. The Company expects full year capital expenditures to be in the range of $190 million to $200 million, inclusive of capitalized interest and internal labor and overhead, and have a year-end cash balance in excess of $50 million."

16:20 EDT Roblox reports April revenue $189M-$192M, up 30%-32% y/y - Reports April: Bookings were between $221M and $224M, down 8% - 10% year over year; DAUs were 53.1M, up 23% year over year; Hours Engaged were 3.8B, up 18% year over year; ABPDAU were between $4.16 - $4.22, down 25%-26% year over year.

16:14 EDT Hologic announces FDA approval of Aptima CMV Quant Assay for Cytomegalovirus - Hologic "announced that the U.S. Food and Drug Administration approved its Aptima CMV Quant assay to quantify the viral load of cytomegalovirus in patients who have had solid organ or stem cell transplants. The test is the first to be introduced in the U.S. by Hologic for post-transplant pathogen detection and monitoring on Hologic's fully automated Panther system, and joins the existing portfolio of diagnostic and viral load testing for HIV-1, Hepatitis C and Hepatitis B. CMV is a common virus that typically causes mild or asymptomatic infections in people with healthy immune systems. However, transplant recipients typically are artificially immunosuppressed to prevent transplant rejection, which makes them more vulnerable to infections. If left untreated, CMV infection can lead to severe disease, transplant rejection and even death. Guidelines from the American Society of Transplantation and the World Health Organization recommend CMV monitoring as standard of care to help guide treatment decisions for transplant patients, depending on their risk and transplant organ type."

16:08 EDT Rocket Companies sees Q2 closed loan volume $35B-$40B - Sees Q2: Net rate lock volume of between $31B-$38B. Gain on sale margins of 2.60%-2.90%.

16:01 EDT Unity Biotechnology announces upcoming milestones - Upcoming Milestones: UBX1325 12-week safety and efficacy data from BEHOLD, the Phase 2a DME clinical trial by mid-year 2022, as well as 24-week safety and efficacy data before year-end 2022; UBX1325 16-week safety and efficacy data from ENVISION, the Phase 2 wAMD clinical trial expected in Q4 2022; Tie2/VEGF bispecific preclinical data to support selection of advanced candidate by mid-year 2022

16:00 EDT Silence Therapeutics PLC (ADS) trading resumes

15:59 EDT Silence Therapeutics PLC (ADS) trading halted, volatility trading pause

15:53 EDT Agilent reports expanded CE-IVD mark in Europe for companion diagnostic - Agilent Technologies (A) announced that its PD-L1 IHC 22C3 pharmDx, Code SK006, is now EU CE-IVD-marked for use in cervical cancer. PD-L1 IHC 22C3 pharmDx can be used as an aid in identifying cervical cancer patients for whom treatment with Merck's (MRK) Keytruda may be appropriate, the company noted.

15:42 EDT Switch up 4% after Bloomberg says DigitalBridge near takeover deal - Switch (SWCH) shares are up $1.34, or 4%, to $31.15 following Bloomberg's report while DigitalBridge (DBRG) shares are down 30c, or 5%, to $5.51.

14:58 EDT Stealth Biotherapeutics granted FDA Orphan Designation for DMD treatment - The FDA said that Stealth Biotherapeutics' treatment of Duchenne Muscular Dystrophy, or DMD, has been granted Orphan Designation status, but not approved for Orphan Indication. Reference Link

14:31 EDT Western Digital says 'begun the process' of passing on inflationary costs - Western Digital executives said they have "begun the process" of passing on inflationary costs, noting price increases that were made during the quarter. Western Digital executives continue speaking in a Q&A session during the company's investor day meeting.

14:10 EDT Western Digital sees 3-5 year revenue growth CAGR of 7%-9% - Western Digital shared 3-5 year financial targets at its investor day meeting, including a total company revenue compound annual growth rate, or CAGR, of 7%-9%, non-GAAP gross margin of 33%-36%, non-GAAP operating margin of 17%-22% and cash capex as a percentage of revenue of 8%-10%. Guidance from slides presented during the investor event.

14:00 EDT Blue Water Vaccines Inc trading resumes

13:55 EDT Blue Water Vaccines Inc trading halted, volatility trading pause

13:43 EDT OTR Acquisition Corporation (Class A Stock) trading halted, volatility trading pause

13:04 EDT Consolidated Water wins $20M desalination plant contract in Cayman Islands - Consolidated Water has signed a definitive agreement with the Water Authority of the Cayman Islands for its planned seawater reverse osmosis plant in George Town, Grand Cayman. Consolidated Water will design, construct and commission the plant over approximately the next 18 months and then sell the facility to the Authority. The company will subsequently operate and maintain the plant and produce water for 10 years after commissioning. The plant will produce up to 2.64M gallons of potable water per day using two independent reverse osmosis trains. The company expects revenue generated over the approximate 11.5-year term of the contract to total about $20M, based on January 2022 values. The majority of the revenue is expected to be generated by the construction and sale of the plant during the first 18 months. The construction fee is subject to an inflation adjustment on January 1, 2023, with operating fees adjusted annually for inflation over the term of the engagement. When the plant is completed as expected in the fourth quarter of 2023, it will be the ninth seawater reverse osmosis desalination plant that Consolidated Water has constructed on Grand Cayman.

12:46 EDT Aileron to make oral presentation of non-clinical data on ALRN-6924 at SID - Aileron Therapeutics announced a late-breaking oral presentation at the upcoming Society for Investigative Dermatology, or SID, Annual Meeting, which will be held May 18-21. "Chemotherapy-induced toxicities range from severe and life-threatening to those that impact and diminish patients' quality of life, sometimes long after chemotherapy has been completed. These toxicities occur because chemotherapy destroys normal, healthy cells while simultaneously destroying cancer cells. Previously, we showed chemoprotection against severe bone marrow toxicities in small cell lung cancer patients receiving topotecan and demonstrated in healthy volunteers the mechanism of action - cell cycle arrest - underlying this chemoprotection benefit. We are excited to now present new data that may suggest ALRN-6924's ability to also protect against chemotherapy-induced hair loss, another devastating chemotherapy-induced side effect for millions of cancer patients," said Manuel Aivado, M.D., Ph.D., President and CEO at Aileron.

12:19 EDT Carvana eliminating 2,500 jobs, executives forgoing salaries for rest of 2022 - Carvana announced a workforce reduction of approximately 2,500 employees primarily in operational groups in connection with its previously announced plans to better align staffing and expense levels with sales volumes. All impacted team members will have the opportunity to receive four weeks of pay plus an additional week for every year they have been with Carvana. The executive team is foregoing their salaries for the remainder of the year to help contribute to the severance pay for departing team members. In connection with these right-sizing initiatives, over the next several weeks Carvana will be transitioning operations away from its Euclid, OH IRC and a few logistics hubs. "We believe these decisions, while extremely difficult, will result in Carvana restoring a better balance between its sales volumes and staffing levels and facilitate Carvana returning to efficient growth on its mission to change the way people buy and sell cars," the company said in a regulatory filing.

12:01 EDT Bausch Health falls -24.0% - Bausch Health is down -24.0%, or -$3.09 to $9.81.

12:00 EDT Kaleyra falls -37.6% - Kaleyra is down -37.6%, or -$2.29 to $3.80.

12:00 EDT Myovant Sciences rises 16.1% - Myovant Sciences is up 16.1%, or $1.25 to $9.03.

11:47 EDT Famatown urges International Seaways to add two new directors to board - Famatown Finance, a company indirectly controlled by trusts settled by John Fredriksen and a member of the Seatankers Group, which is the largest owner of shares of common stock, no par value of International Seaways with ownership of approximately 16.6% of the outstanding Common Stock, has issued an open letter to the Board of Directors of International Seaways. The letter read in part, "The Seatankers Group holds significant interests within industries such as shipping and energy, oil services and diversified industrials. These investments include, among others, a strategic ownership position in 15 publicly listed companies where the Seatankers Group proactively works with the management teams and Boards of Directors of such companies with the ambition of creating shareholder value. Part of the Seatankers Group's DNA is to think and act like an investor with a focus on value maximization for the shareholders at all times. Significant dividend distribution and value creation has been created through the Seatankers Group's involvement in public shipping companies over the last cycles. The Seatankers Group accumulated a position in International Seaways with the view of International Seaways representing an attractive platform with exposure to a product and crude oil transportation market, which is in the early stage of a global recovery. International Seaways' share price and return to shareholders has for a prolonged time underperformed relative to peers. With decades of experience and network in the maritime transportation industry, the Seatankers Group is confident it could help unlock further shareholder value in International Seaways. The Seatankers Group was therefore extremely disappointed with International Seaways' recent implementation of a poison pill, which was adopted without shareholder approval and without any material dialogue with the Seatankers Group. This poison pill will hinder communication with shareholders regarding strategic decisions and will not allow shareholders to realize the full value of their investments. The Seatankers Group's ambition with its ownership in International Seaways is still to create long-term shareholder value consistent with what it has been able to accomplish with its involvement with many other companies in the industry. To achieve this, the Seatankers Group urges International Seaways to add two new Directors to its Board of Directors chosen in consultation with the Seatankers Group...The Seatankers Group urges International Seaways' management team and Board of Directors to constructively collaborate with the Seatankers Group and support the election of two additional Directors."

11:12 EDT DecisionPoint Systems Inc trading resumes

11:09 EDT SoFi Technologies down 16% to $5.01 after Bloomberg reveals Q1 results

10:49 EDT Evotec, Bristol-Myers extend, expand strategic partnership - Evotec (EVO) announced that the Company has extended and expanded its partnership with Bristol Myers Squibb (BMY) in targeted protein degradation, originally signed in 2018. The initial collaboration has proven to be highly productive in generating a promising pipeline of molecular glue degraders. Based on this success, Bristol Myers Squibb and Evotec extend and expand this partnership for an additional 8 years with the goal to further broaden and deepen the strategic alliance. Molecular glue degraders are small, drug-like compounds that induce interactions between an E3 ubiquitin ligase and a molecular target. This induced interaction results in ubiquitination and subsequent degradation of the recruited protein leading to long-lasting therapeutic effects. Bristol Myers Squibb is a leader in this field based in particular on its unique library of cereblon E3 ligase modulator. Under the terms of the agreement, both parties will leverage all of Evotec's proprietary EVO panOmics and EVO panHunter platforms as well as AI/ML-based drug discovery and development platforms. Evotec receives an upfront payment of $200M and expects to obtain further performance-based, near-term and programme-based milestone payments, resulting in a deal potential of $5B with additional tiered royalties on product sales.

10:31 EDT Precipio signs first IV-Cell customer agreement - Precipio announced that American Oncology Network of Fort Myers, Florida, has completed its validation of Precipio's proprietary IV-Cell culture media, and will adopt the product for use in its clinical cytogenetics laboratory.

10:22 EDT AMCI Acquisition reports filing of registration statement regarding combination - AMCI Acquisition Corp. II and LanzaTech NZ announced that AMCI has filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission on May 10, 2022 in connection with its proposed business combination with LanzaTech. The combined company is expected to be listed on Nasdaq upon completion of the proposed business combination. The proposed business combination is expected to close in the second half of 2022 and is subject to, among other things, the approval by AMCI's stockholders and LanzaTech's stockholders and the satisfaction or waiver of other customary closing conditions.

10:08 EDT Sysco 'concerned' about long-term impact of elevated inflation

10:07 EDT Sysco: Omicron impacts felt through February - Comments taken from Q3 earnings conference call.

10:05 EDT Lakewood Township, NJ announces new bill pay kiosks with CityBase - CityBase announced a new engagement with the Township of Lakewood, NJ. Lakewood will introduce new kiosk bill payment machines to support in-person payments for various municipal bills. CityBase is a business unit of GTY Technology Holdings,

10:00 EDT Huadi International Group Company Ltd trading halted, volatility trading pause

10:00 EDT Bausch Health falls -28.9% - Bausch Health is down -28.9%, or -$3.73 to $9.18.

10:00 EDT Kaleyra falls -38.7% - Kaleyra is down -38.7%, or -$2.35 to $3.73.

10:00 EDT Haemonetics rises 16.0% - Haemonetics is up 16.0%, or $7.89 to $57.16.

09:48 EDT TNON Stock trading resumes

09:47 EDT FutureFuel falls -28.9% - FutureFuel is down -28.9%, or -$2.86 to $7.02.

09:47 EDT Coupang rises 14.7% - Coupang is up 14.7%, or $1.37 to $10.72.

09:47 EDT Biohaven Pharmaceutical rises 70.7% - Biohaven Pharmaceutical is up 70.7%, or $58.76 to $141.90.

09:40 EDT Pegasystems trading resumes

09:40 EDT Fusion Fuel Green PLC trading resumes

09:40 EDT IDEAYA Biosciences trading resumes

09:37 EDT Lemonade trading resumes

09:36 EDT Upstart Holdings trading resumes

09:35 EDT Pegasystems trading halted, volatility trading pause

09:34 EDT Creatd announces entry into print publishing, partnership with Unbound - Creatd announced that Creatd Studios, its transmedia production arm, will bring Vocal creators from the digital realm to bookshelves, beginning with the upcoming release of a fiction anthology featuring original stories sourced from Vocal creators. The book will be published in partnership with Unbound, hailed as the world's first crowdfunded publisher. Creatd's inaugural book will be a collection of short fiction, featuring the 25 winning stories from The Vocal+ Fiction Awards, Vocal's recent fiction-focused Challenge which generated over 13,000 creator submissions. In addition to inclusion in the book, Challenge winners received a $5,000 reward.

09:32 EDT Lemonade trading halted, volatility trading pause

09:31 EDT ALX Oncology trading halted, volatility trading pause

09:30 EDT Kura Oncology trading halted, volatility trading pause

09:30 EDT IDEAYA Biosciences trading halted, volatility trading pause

09:30 EDT National Vision Holdings trading halted, volatility trading pause

09:29 EDT TeraWulf issues statement reiterating plans for Nautilus Cryptomine facility - TeraWulf issued the following statement regarding the Nautilus Cryptomine facility in Pennsylvania, which is a 50/50 joint venture between TeraWulf and Talen Energy: "The Nautilus Cryptomine facility, which is a joint venture between TeraWulf and Cumulus Coin, LLC, a subsidiary of Talen, remains on track to begin bitcoin mining operations in the third quarter of 2022. The joint venture has been funded by both joint venture partners and is continuing its infrastructure buildout under the direction of the Nautilus Cryptomine team. Importantly, Cumulus Coin, a subsidiary of Cumulus Growth Holdings, LLC, is excluded from the Chapter 11 proceedings initiated on May 9, 2022 by Talen Energy Supply, LLC and affiliated debtors in the U.S. Bankruptcy Court for the Southern District of Texas. Once complete, the Nautilus Cryptomine facility is expected to reach 300 MW - with 150 MW attributable to TeraWulf - and will benefit from long-term, zero-carbon power supply directly from the Susquehanna nuclear power generation station."

09:27 EDT Alkaline88 1-liter 12-pack to be available in 8,000 locations of drugstore chain - The Alkaline Water Company announced that the country's largest drugstore chain will carry the Alkaline88 1-Liter 12 pack as part of a special summer promotion. The 12-pack is already on shelves in many of the drugstore chain's stores across the country and will soon be available in approximately 8,000 total chain locations throughout the summer.

09:25 EDT Duke Realty jumps 18% to $56.53 after Prologis buyout proposal

09:23 EDT Rockley Photonics competes preliminary human study measuring hydration levels - Rockley Photonics announced that the company has successfully completed its preliminary human study measuring hydration levels using Rockley's non-invasive biomarker sensing platform. Rockley has also created a new hydration index for reporting relative hydration levels with the potential to simplify the complex process of measuring personal hydration. Preliminary results of Rockley's human study examining active hydration levels before, during, and after exercise show that the miniaturized photonics-based sensor in the Rockley biosensing platform can monitor water absorption and is sensitive to water concentration changes in different layers of the dermis. The study shows that a Rockley wearable device was able to correctly predict dehydration in human subjects 99% of the time and detect the normal state of body water content euhydration 82% of the time. The ability to monitor changes in body water levels on a routine basis through a Rockley-powered device has the potential to help people and healthcare professionals make better-informed choices about their personal and patient hydration needs, respectively, including the amount and timing of fluid consumption.

09:21 EDT HIVE-ZOX selects Sierra Wireless module to check COVID vaccines shipments - Sierra Wireless announced that its HL78 Series LPWA module has been chosen by HIVE-ZOX International to provide global connectivity and real-time visibility for their cold chain monitoring solution. The solution is currently being used to monitor COVID vaccine shipments and provide quality control throughout the supply chain, all over the world. Sierra Wireless' multi-mode LPWA modules offer best-in-class power performance for global LTE-M, NB-IoT, and 2G networks, providing seamless global connectivity for the HIVE-ZOX solution. They offer a wide selection of bands for scalability across the world, and their high transmit power ensure a resilient connection, even in challenging underground or remote locations.

09:19 EDT Tetra Tech, Cognite partner to accelerate digitization in energy utility space - Tetra Tech announced our strategic partnership with Cognite. The partnership combines Tetra Tech's utility management consulting expertise with Cognite's leading Industrial DataOps platform, Cognite Data Fusion, to help energy utilities remove data silos and enable users to collaborate quickly and safely to develop, operationalize, and scale industrial AI solutions and applications. Together, Tetra Tech and Cognite will enable utilities to increase resilience and drive decarbonization with digital twin-based technology and practices for predictive maintenance, digital inspections, and system analytics. Cognite Data Fusion will augment the Tetra Tech Delta suite of proprietary technologies and analytical tools and is part of our Leading with Science approach to deliver clear solutions to the most complex client challenges. Cognite will add its technical and development support for implementation within the utility technology ecosystem to Tetra Tech's deep and detailed utility operations experience to advance accelerated adoption and change management in asset management and maintenance.

09:17 EDT Stratasys introduces GrabCAD Print software - Stratasys introduced GrabCAD Print for the Stratasys Origin One and Origin One Dental 3D printers. An application of the GrabCAD Additive Manufacturing Platform, GrabCAD Print will provide users with an integrated, all-in-one software solution for streamlining the 3D printing workflow for print build file preparation and post print analysis. The integration with GrabCAD Print is the first step in integrating Origin One into the full platform. The GrabCAD Additive Manufacturing Platform enables two-way connectivity between 3D printers, additive manufacturing and enterprise applications, and broader Industry 4.0 infrastructure. The open and enterprise-ready platform brings together GrabCAD applications and third-party GrabCAD Software Partners via the GrabCAD Software Development Kit. This ecosystem approach enables manufacturers to manage their production-scale additive manufacturing operations across the entire digital thread - from design through production. GrabCAD Print for Origin One will provide an alternative to 3rd party pre-print software solutions, providing users with a consistent user experience and connectivity with Stratasys 3D printing technologies while replacing the native Origin web application.

09:16 EDT Stratasys announces expansion of F123 Series of 3D printers - Stratasys announced that the company has expanded its F123 Series of 3D printers with the introduction of the F190 CR and F370 CR 3D printers, plus new FDM Nylon-CF10 material reinforced with carbon fiber. The new printers offer high stiffness and strength materials in a hardened machine ready for composite material printing. The new composite 3D printers are designed for manufacturers and industrial machinists to supplement traditional fabrication technologies with high-strength composite 3D printing. The printers help manufacturers produce end use parts faster and more cost-effectively, and are ideal for jigs, fixtures and workholding tools.

09:16 EDT Momentive launches Idea Screening for AI-powered insights - Momentive announced the availability of Idea Screening, a new insights solution for concept and creative testing. The solution is designed to provide quick, AI-powered insights on early-stage ideas, claims, or concepts so product and marketing professionals can test idea saliency and effectiveness before investing in further development, Momentive said in a statement.

09:14 EDT Clarus announces notice of allowance from USPTO for claims covering CLAR-121 - Clarus Therapeutics announced that it has received a notice of allowance from the United States Patent and Trademark Office, USPTO, for claims that cover certain methods for the treatment of autoimmune inflammatory mastitis that can be achieved by its product candidate, CLAR-121, a proprietary combination of testosterone and anastrozole delivered by a subcutaneous implant. Patent application No. 17/437,525 is entitled "Pharmaceutical Formulations and Systems for Delivery of an Androgenic Agent and an Aromatase Inhibitor with Sustained Multi-Phasic Release Profiles and Methods of Use." The U.S. patent scheduled to issue from this application will expire in June 2040. "We are thrilled to further establish intellectual property protection for our pipeline," said Dr. Robert Dudley, President and Chief Executive Officer of Clarus. "We believe this notice of allowance validates the innovation behind CLAR-121 and supports this novel approach for treating androgen-mediated inflammatory breast diseases. Our initial focus for CLAR-121 will be for the treatment of PDM, a painful condition of inflamed breast tissue that predominantly affects women and for which there is currently no available drug interventions. We are currently seeking Orphan Drug Designation from the FDA for CLAR-121 for the treatment of PDM in the second quarter of 2022 and anticipate initiating a Phase 2 clinical trial in the second half of 2022."

09:14 EDT Avantor and Cytovance sign agreement to research and GMP grade plasmids - Avantor and Cytovance Biologics, have entered into an agreement to manufacture, research and GMP grade plasmids for biopharma customers. This collaboration extends Avantor's leadership in providing critical materials for next-generation vaccines and therapeutics focused on cell and gene therapy and mRNA drug manufacturing and expands Cytovance Biologics' global commercial reach. Plasmid DNA is one of the most critical process elements in viral vector-based gene therapy and mRNA vaccines and therapeutics. This new relationship will allow Avantor to provide global biopharma customers and contract manufacturing organizations access to plasmid DNA and other mission-critical inputs used in research, clinical testing and manufacturing scale-up and commercialization by leveraging Cytovance Biologics' plasmid cGMP manufacturing capabilities.

09:13 EDT Qualtrics and SAP partner to bring more 'empathy' to contact center - Qualtrics (XM) announced a new integration that brings Qualtrics XM Discover's AI and machine learning capabilities into SAP Service Cloud (SAP )to help customer service teams resolve customer issues, increase resolution rate and improve customer satisfaction. "Experience Management is foundational for any intelligent and sustainable enterprise, helping them achieve higher levels of customer loyalty," said

09:12 EDT Payoneer Global launches Payoneer Checkout - Payoneer announces the launch of Payoneer Checkout, marking the company's entry into payment acceptance for direct-to-consumer webstores. The company said, "Building on its leadership in marketplace payments and B2B payments, the launch of Payoneer Checkout creates a unified experience for Payoneer's eCommerce merchants across multiple digital channels. By consolidating all their funds across marketplace and direct sales channels in Payoneer's multi-currency accounts, merchants can manage their accounts payable needs, gain access to working capital, and use their funds to pay for business expenses such as digital advertising. Payoneer Checkout is currently available in Asia-Pacific and will gradually be extended globally."

09:11 EDT Volta launches Store Next Door offering - Volta launched its new Store Next Door place-based targeting offering. This product brings the power of the Volta Media Network to more verticals by enabling location targeting based on the stores adjacent to Volta's EV charging stations and media screens. The Store Next Door offering expands the categories advertisers can use to target Volta's highly visible, 55" digital media screens from just the main store to nearly 40 unique options, including healthcare centers, gyms, pet stores, and quick service restaurants. For example, an apparel brand can now target Volta media screens located one or two doors down from sporting goods stores that share the same parking lot as Volta's charging stations. This new capability was made possible by Volta's data-driven understanding of commercial real estate design, parking lot configurations, and shopper behavior.

09:10 EDT Comtech appoints Ken Peterman to board of directors - Comtech Telecommunications announced today that it had appointed Ken Peterman to Comtech's Board of Directors. Ken will join the Board's Science and Technology Committee. Most recently, as President at Viasat Government Systems, Peterman led a world-class satellite communications, mobile networking and cybersecurity portfolio.

09:09 EDT DMG Blockchain Solutions names Steven Eliscu as COO - DMG Blockchain Solutions announces that Steven Eliscu has joined the management team as COO. Eliscu was previously an Independent Director of the company.

09:08 EDT Health Canada approves Eurofins CDMO Alphora's standard processing license - Eurofins CDMO Alphora Inc. announces receipt in April 2022 of its Health Canada Standard Processing License issued within the Cannabis Act and Cannabis Regulations for its Oakville, Ontario Operations. This is complementary to the Institutional Research License obtained through Health Canada in June 2021 for its Mississauga development site. Eurofins CDMO Alphora Inc. entered a licensing agreement with Kare Chemical Technologies Inc. in August 2021 for use of Kare's innovative technology to synthetically produce high quality phytocannabinoids. Eurofins CDMO Alphora Inc. has since developed scalable processes for several naturally occurring phytocannabinoids including CBD, CBDv, THC, THCv, and is preparing processes for others such as CBN, CBDA.

09:07 EDT Verb Technology partners with Momentum Factor - Verb Technology announces its partnership with Momentum Factor, makers of FieldWatch and the leading digital risk management firm specializing in online compliance monitoring and global online reputation management services and technologies. The partnership provides direct sales companies with the first of its kind social compliance solution. By integrating Momentum Factor's FieldCheck platform with VERB's customer relationship and content management application, verbCRM, field representatives can review and post their social messages with confidence, knowing that FieldCheck reviews each post for keywords or phrases that are not following regulatory compliance or company guidelines, including FTC and FDA compliance. "We are very excited about partnering with a company of Verb's stature in the direct sales market," said Jonathan Gilliam, CEO & Founder of Momentum Factor. "Having FieldCheck fully integrated within verbCRM will be a difference maker for both compliance teams and field representatives within the direct selling industry."

09:06 EDT General Motors, Red Hat collaborate on software-defined vehicles - Red Hat and General Motors announced a collaboration to help advance software-defined vehicles at the edge. The companies expect to expand an ecosystem of innovation around the Red Hat In-Vehicle Operating System, which provides a functional-safety certified Linux operating system foundation intended for the ongoing evolution of GM's Ultifi software platform. The collaboration between Red Hat and GM is a significant moment in the convergence of the transportation and technology industries, with Red Hat's cloud-native, enterprise-grade open source operating system accelerating the development of GM's software-defined vehicle programs following Ultifi's initial launch. This will enable both companies to offer customers more valuable features responsibly in a fraction of the typical development time. Red Hat will contribute to the phased rollout of Ultifi, GM's end-to-end vehicle software platform which will launch in 2023. Ultifi will enable a frequent and more seamless delivery of software-defined features, apps and services to customers over-the-air. To do this, the platform separates the application software from the hardware to offer application program interfaces for software development. Creating a more flexible architecture unlocks the potential for more cloud-based services, faster software development and new value for customers without affecting basic hardware controls.

09:05 EDT CareTrust REIT announces transfer to NYSE - CareTrust REIT announced the pending transfer of its common stock from the Nasdaq Global Select Market to the New York Stock Exchange. The company expects its common stock to begin trading on the NYSE at market open on May 23, 2022 under its current ticker symbol "CTRE." The Company's common stock will continue to trade on Nasdaq until the transfer is complete.

09:04 EDT Mondelez sees adjusted EPS growth in high single digits on CC basis - The company continues to expect Adjusted EPS growth on a constant currency basis in the high single digits and gradually increasing Free Cash Flow of $3 billion plus over the long term. The company is confident it can accelerate and sustain profitable growth and achieve this refined long-term algorithm as a result of: Increasing portfolio focus on the core of chocolate and biscuits; Taking both organic and inorganic steps to fill geographic white spaces; Expanding distribution in high-growth channels where the company has clear headroom to grow Increasing presence in under-represented segments and price tiers.

09:03 EDT Mondelez to divest developed market gum business, global Halls business - The company announced plans to divest its developed market gum business after completing a strategic review over the past year. The company also disclosed its intention to divest the global Halls business. Mondelez International will continue to operate other brands and products within its candy business, as well as its emerging market gum business.

09:03 EDT WISeKey announces Swiss Intrinsiq Security for Watchmakers' Brand Protection - WISeKey International announced a new Swiss Intrinsiq Security for Watchmakers' Brand Protection. The secure element to digitally prove the identity of a luxury good is no longer an external "dirty" part that is artificially affixed onto/into the product. It is fully integrated and becomes a constitutive part of the product. The overall luxury perception is intact. The authenticity of the luxury good can be easily proven by checking the digital identity contained in the embedded secure element through standard cryptographic transactions between this "chip" and an external authentication device. Various interfaces are possible. The embedded secure element can also contain the full certified history of the luxury good from manufacturing to customers which solves the traceability complexity of these products. Moreover, the silicon used to manufacture the mechanical parts offers additional useful characteristics.

09:02 EDT Ingevity granted certificate of marine environment biodegradability - Ingevity announced its Capa thermoplastic grades obtained the OK biodegradable MARINE certification by TundefinedV Austria Bureau of Inspection and Certification. OK biodegradable MARINE confirms Capa thermoplastics fully biodegrade in a marine environment within four weeks, prohibiting formation of persistent microplastics and enabling a safer marine ecosystem than traditional plastics made with alternative chemistries.

09:01 EDT DoorDash, FaZe Clan announce partnership - FaZe Clan, the lifestyle and media platform rooted in gaming and youth culture, announced a partnership with local commerce platform DoorDash. The partnership includes both content and marketing initiatives, with DoorDash appearing across FaZe Clan's platforms as their official on-demand delivery platform. Throughout the partnership, FaZe Clan Talent including FaZe Nate Hill, FaZe Adapt, FaZe Faxuty, FaZe Kalei, FaZe Swagg, FaZe ZooMaa and more to be announced will partner with DoorDash and highlight how DoorDash helps them stay in their game by seamlessly connecting them to their gaming essentials. FaZe Clan and DoorDash have also teamed up for a new livestream gaming series on Twitch called DashDays, where FaZe Clan members will bring unique opportunities to their fans by dropping DoorDash codes, FaZe Clan merchandise and other surprises. Additionally, DoorDash will be integrated into Faze Clan's slate of new and innovative programming. The partnership will also extend outside of the digital realm to include innovative live events that fuel the synergy between gaming, food, and more.

08:52 EDT Novamind to host Bionomics PREVAIL Trial for treatment of SAD - Novamind announced it has been selected to host a clinical trial for the acute treatment of social anxiety disorder, an understudied and common mental health condition that affects nearly 15 million American adults. The phase II randomized clinical study for the acute treatment of SAD is sponsored by Bionomics Limited, a clinical-stage biopharmaceutical company and is currently enrolling patients at Novamind's Draper, Utah, research site. The PREVAIL Trial will examine the safety and efficacy of Bionomics' propriety drug candidate, BNC210, versus a placebo in reducing self-reported anxiety severity when participants take part in an anxiety-provoking behavioral task involving a speaking challenge. People with SAD experience extreme fear in social situations, when meeting new people or speaking in front of others, which can severely and negatively impact relationships, work and daily life. Current medical interventions include SSRIs, beta-blockers and anti-anxiety medications such as benzodiazepines. The PREVAIL Trial is the second Bionomics study hosted by Novamind. In 2021, the Company announced it was selected to host a phase IIb randomized clinical trial investigating BNC210 as a treatment for PTSD. BNC210 has Fast Track designations from the U.S. Food and Drug Administration for the treatment of both PTSD and SAD, a process designed to facilitate development and expedite the review of drugs that address an unmet medical need for serious conditions.

08:48 EDT Evofem selects Bora Pharmaceuticals Services Canada as new CMO - Evofem Biosciences announced it has selected Bora Pharmaceuticals Services Canada as Evofem's new contract manufacturing organization, or CMO. Bora will eventually manufacture Phexxi for markets worldwide. "With this arrangement, Evofem expects to realize a 45% reduction in the cost of goods related to the manufacturing, packaging, and testing of Phexxi as part of the company's overall efforts to reduce spend and continue to improve gross margin," said Saundra Pelletier, CEO. Demand for Phexxi, the hormone-free, on-demand contraceptive, which was FDA-approved in May 2020, continues to grow in the U.S. Evofem recently reported its third consecutive quarter of revenue growth. Evofem has initiated technical transfer activities, and Bora is expected to begin manufacturing Phexxi in the fourth quarter of 2022. Initially, Bora will manufacture Phexxi for nations currently considering formal regulatory approval of Phexxi for the prevention of pregnancy, including Mexico and Nigeria.

08:46 EDT Rubicon announces launch of RUBICONSelect - Rubicon Technologies announced the launch of RUBICONSelect, a new program that allows independently owned waste and recycling haulers to "leverage Rubicon's best-in-class vendor relationships to benefit from special offers, deals, and discounts on valuable business resource," the company said. The program is available to all haulers and businesses on the Rubicon marketplace, and helps them run and grow their businesses by connecting them with brand name vendors with whom Rubicon has an existing partnership. "RUBICONSelect is an incredible new way for independently owned haulers to continue growing through their partnership with Rubicon," said Renaud de Viel Castel, Chief Operating Officer at Rubicon. "Members will be provided with exclusive deals and offers to which they may not have otherwise had access. This program is another example of how Rubicon works every day to support our valued hauler partners. I am proud to announce the launch of this program, and to be involved in a project that provides those opportunities."

08:45 EDT Ondas says Scotts Miracle-Gro to use American Robotics' autonomous drones - Ondas Holdings announced that American Robotics received a new purchase order from The Scotts MiracleGro Company for its autonomous, FAA-approved Scout Systems, which will provide the company with daily data collection and analytics capabilities. With this purchase, American Robotics continues its expansion into key commercial markets. American Robotics' drone systems will be installed at the ScottsMiracle-Gro headquarters in Marysville, Ohio, and operations will kick off in Q2 of 2022. Implementing autonomous drones at this location will allow employees to efficiently and cost-effectively analyze high-fidelity field data in near-real time. American Robotics' fully-automated drone systems can conduct multiple missions per day without a human observer on the ground, providing the ability to track and analyze data without physically sending employees into the field.

08:44 EDT Airtrax's subsidiary RAD receives order for 2 AVA, 1 Wally security robots - Artificial Intelligence Technology Solutions announced that its wholly owned subsidiary Robotic Assistance Devices, RAD, has received an order for 2 AVA and 1 Wally security robots from a top ranked global logistics company. Although not named due to confidentiality agreements, the Company indicated that the end-user, and existing client, is a global leader in supply chain management & third-party logistics. The Company did confirm that the 2 AVA autonomous access control security robots are expected to be deployed in June at one of the client's logistics centers. "We love this client, and they apparently love RAD as well," said Steve Reinharz, CEO of AITX. "This client had a hand in helping RAD shape and expand its product offering. As a result, they have just about every type of device, performing various tasks, and saving them a lot of money," Reinharz continued. The Company also confirmed that with the order for these 3 RAD devices brings the client's total units deployed and/or on order to 30. "This is RAD's example of providing great solutions and great customer service to a client, and expecting great continued business," Reinharz concluded.

08:43 EDT Vox provides development, exploration update - Vox Royalty is pleased to provide recent development and exploration updates from royalty operating partners Northern Star Resources, Jangada Mines, Black Cat Syndicate and Gold Standard Ventures. Key Development Updates: Pre-stripping and open pit mining preparation commencement at the Otto Bore gold project by Northern Star; Updated feasibility-level engineering technical report for the Pitombeiras vanadium project by Jangada; Acquisition of Paulsens gold mine by Black Cat, reprioritizing Vox's Merlin and Electric Dingo gold royalty projects and an update on Bulong development timing; and 5,700m drilling planned by Gold Standard Ventures at Railroad Pinion gold project in Nevada from May 2022 onwards, with a second stage exploration program to be completed in the Fall and Winter of 2022. Otto Bore - Pre-Stripping and Open Pit Mining Preparation Commencement: Vox holds a 2.5% net smelter return royalty over the Otto Bore gold project in Western Australia, acquired in conjunction with the producing Janet Ivy / Binduli North gold royalty in March 2021; On April 27, 2022 and May 3, 2022, Northern Star announced that: Preparation for open pit mining operations at the Otto Bore deposit have commenced, confirmed by open pit pre-stripping observed by Vox management via satellite imagery; All required environment studies have been completed and relevant vegetation clearance and a dewatering permit has been granted. The Mining Proposal has been approved, however it will be revised and resubmitted to accommodate extension of the new reserve pit; An average gold recovery for the Otto Bore deposit is estimated at 94% based on met testwork and ongoing long term actual average recovery data collected at the Thunderbox plant. Metallurgical testwork has been carried out on samples from the Otto Bore deposit by processing and test lab, with suggested recoveries could go as high as 97% hence the estimated recovery is in line with expectation; and Northern Star is currently exploring proximal to the Otto Bore deposit and is working on an exploration program which will test the lateral and down dip extents of the Otto Bore mineral resource. Vox Management Summary: The Otto Bore royalty was acquired for a small fraction of the purchase price in Vox's March 2021 royalty portfolio transaction with Horizon Minerals, with the majority of the purchase price allocated to the Janet Ivy gold royalty. Otto Bore has been fast-tracked by Northern Star ahead of Vox management expectations and is now expected to generate attractive revenues for Vox shareholders in 2023. Pitombeiras - Technical Report and Feasibility update. Vox holds a 1% net smelter return royalty over the Pitombeiras vanadium-titanium-iron ore project in Brazil; On April 21, 2022, Jangada announced that: It has updated the Pitombeiras technical report, which supersedes the Preliminary Economic Assessment published in 2021; The updated technical report includes the titanium component at the project and provides for the following updated results: 100.3% post-tax IRR; US$96.5 million post-tax NPV at an 8% discount rate; All-in capital expenditure totalling US$18.5 million; Post-tax payback period of 13 months; Life of Mine approximately 9 years based on the current estimated minable resource of 5.5Mt, producing total forecast tonnages produced of 1.74Mt Fe / V2O5 and 66kt TiO2; US$415 million total gross revenue, applicable to the 1% net smelter royalty; and Exploration potential to increase LOM remains open. Finalisation of the Pitombeiras feasibility study is subject to completion of the titanium by-product credit analysis, which is expected to improve the overall project economics. Vox Management Summary: This technical report outlined a post-tax payback period of 13 months, which is extremely short for modern mining projects, further confirming Vox management's positive expectations about the near-term development likelihood of the Pitombeiras project. Despite the titanium-related scope changes, we still expect a construction decision later in 2022 for this rapidly-advancing vanadium project. Bulong - Production Timing Guidance and Royalty Project Acquisition: Vox holds a 1% net smelter return royalty over part of the Bulong gold project in Western Australia; On April 19, 2022, Black Cat announced that: It has entered into binding agreements to acquire 100% of the high-grade Coyote and Paulsens gold operations from Northern Star for total consideration of up to A$44.5 million. Vox holds a 0.75% gross revenue royalty over the Merlin gold deposit, and a 1.75% gross revenue royalty over the Electric Dingo gold deposit. Both royalties form part of the Paulsens gold operation purchased by Black Cat; and Highlights of the transaction include: Commencement of a substantial exploration program over near-mine & regional targets; and Target decision to mine at Paulsens within 18 - 24 months. In its April 21, 2022, investor presentation, Black Cat highlighted that: As a result of Black Cat's acquisition of the Coyote and Paulsens gold operations, it is now intended that the Bulong project will be mined by Black Cat and toll-treated at an existing gold mill near Kalgoorlie; Black Cat is currently undertaking a tender to mine and toll-treat the fully approved royalty-linked Myhree open pit with interested toll milling parties around Kalgoorlie; and If acceptable toll milling terms are agreed, Black Cat will mine Myhree during 2022/23; Vox Management Summary: Black Cat's strategic acquisition of the Paulsens gold mine unlocks the previously-dormant Merlin and Electric Dingo royalty deposits, which are both proximate to the Paulsens mine processing infrastructure. Vox management remains confident that the toll milling tender for the Myhree deposit presents strong potential for Bulong-linked royalty revenue from 2023 onwards. South Railroad - 2022 Exploration Program & Resource Update Timing: Vox holds a 0.633% net smelter return royalty with advance minimum royalty payments over key portions of the South Railroad gold project, which is located in Nevada's prolific Carlin Trend; On April 18, 2022, Gold Standard Ventures announced that: The first stage exploration program for 2022 includes approximately 5,700m of reverse-circulation and core drilling over 20 holes with drilling scheduled to start in May 2022; The first stage drilling includes 3,050m targeting the royalty-linked Pinion SB Zone Target, with the objectives of testing the continuity and limits of the SB Zone and a goal to include certain areas of the Pinion SB Zone into an updated Pinion Mineral Resource near year-end 2022. Based on the results of the first stage exploration program, Gold Standard Ventures intends to develop a second stage exploration program to be completed in the Fall and Winter of 2022; and Vox Management Summary: 2022 drilling at the royalty-linked Pinion SB Zone is expected to increase mineral resources in late 2022 and ultimately support longer-life royalty revenues for Vox shareholders. Gold Standard Ventures management is still targeting first production in mid-2024 for this exciting Nevada gold project.

08:42 EDT ABVC BioPharma reports first subject treated in Phase II part 2 ADHD study - ABVC Biopharma announced that the first subject began treatment at the Cheng Hsin General Hospital in the Phase II part 2 clinical study of the company's ADHD medicine. The study, entitled "A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients with Attention-Deficit Hyperactivity Disorder, Part II," is a randomized, double-blind, placebo-controlled study involving a total of approximately 100 patients in the United States and Taiwan. This is a continuation of the Phase II part 1 study of ABV-1505, which was completed successfully at the University of California, San Francisco and accepted by the U.S. Food & Drug Administration in October 2020.

08:41 EDT United Rentals in pact with Ford to purchase all-electric vehicles for fleets - United Rentals (URI), announced a new agreement with Ford (F) Pro to purchase all-electric vehicles for its North American rental and company fleets. The agreement initially includes orders for 500 F-150 Lightning trucks and 30 E-Transit vans, with 120 trucks and all 30 vans to be delivered in 2022. The vehicles will be used by United Rentals customers on construction and industrial jobsites, and by the company's sales, service and delivery personnel. United Rentals has selected the Ford F-150 Lightning model with a maximum target range of 320 miles and a maximum towing capacity of 10,000 lbs. The E-Transit is an all-electric commercial cargo van with a target range of 126 miles. Both models are equipped with Pro Power On-board and an array of connectivity features, including F-150 Lightning's game changing technology - Intelligent Back-Up Power. The company expects to deploy the vehicles in the second half of 2022.

08:39 EDT Scynexis presents interim data of ibrexafungerp from Phase 3 FURI study - SCYNEXIS announced the presentation of new positive outcomes in patients with refractory vulvovaginal candidiasis, VVC, treated with oral ibrexafungerp from the ongoing Phase 3 FURI study. The new interim analysis was presented during the American College of Obstetricians and Gynecologists, ACOG, Annual Clinical & Scientific Meeting held in San Diego on May 6-8, 2022. "We are extremely encouraged by these data showing positive outcomes in VVC patients with severe refractory or relapsed infections," said David Angulo, M.D., Chief Medical Officer of SCYNEXIS. "We are committed to making advancements in the area of women's health and believe these outcomes underscore the potential clinical utility of this novel agent in the treatment of a broad spectrum of VVC cases." Of the 14 patients in the FURI study with refractory or relapsed cases of VVC treated with ibrexafungerp, 10 had successful clinical outcomes as judged by an independent Data Review Committee. Patients with VVC received 750 mg of oral ibrexafungerp every 72 hours for a total of three dosing days. The ongoing Phase 3 open-label, single-arm FURI study is evaluating oral ibrexafungerp for the treatment of patients with severe fungal infections who are either intolerant to standard antifungal therapy or experience refractory fungal infections despite treatment. In the study, ibrexafungerp was generally safe and well-tolerated with findings consistent with the existing BREXAFEMME label.

08:37 EDT Moleculin Biotech receives approval from UK MHRA for Phase 1a study of WP1122 - Moleculin Biotech announced that it has received approval from the UK MHRA to proceed with a first-in-human Phase 1a study to evaluate the safety and pharmacokinetics of WP1122 in healthy volunteers for the treatment of COVID-19, or MB-301. The approval follows Moleculin's having submitted a protocol amendment allowing for a higher ratio of diluting excipients to drug substance to facilitate a faster and simpler mixing procedure before drug administration. WP1122, the Company's lead metabolism/glycosylation inhibitor, is a prodrug of a well-known glucose decoy called 2-deoxy-D-glucose, or 2-DG, currently being developed for inhibition of viral replication and disease manifestations in humans infected with SARS-CoV-2, the virus responsible for COVID-19. The mechanism of action of 2-DG includes both the inhibition of glycolysis and the disruption of glycosylation, two processes that are important to both viral activity and tumor development. WP1122 was developed as a 2-DG prodrug to provide a more favorable pharmacological profile, and was found to have greater potency than 2-DG alone in preclinical models where tumor cells require higher glycolytic activity than normal cells. WP1122 has also been shown to have a more potent antiviral effect than 2-DG against SARS-CoV-2 in MRC-5 cells in culture.

08:37 EDT Star Equity issues open letter to Superior Drilling board - Star Equity Fund, LP and affiliates, a shareholder of Superior Drilling Products, issued an open letter to SDPI's Board of Directors. The letter says in part: "We strongly believe to best achieve these goals SDPI should become part of a larger entity. The most likely way for this to happen would be for SDPI to sell itself to a larger company. The Company could also pursue a merger of equals or allow a larger private company to go public via a reverse merger into SDPI. Alternatively, SDPI could be taken private if none of these options materialize. We strongly believe all these strategic options should be considered by the Board and pursued with a sense of urgency. Remaining a small public company is a poor outcome for shareholders due to the Company's microcap status and its high SG&A expenses, including management compensation and public-company costs, as a percentage of revenue. We strongly believe to best achieve these goals SDPI should become part of a larger entity. The most likely way for this to happen would be for SDPI to sell itself to a larger company. The Company could also pursue a merger of equals or allow a larger private company to go public via a reverse merger into SDPI. Alternatively, SDPI could be taken private if none of these options materialize. We strongly believe all these strategic options should be considered by the Board and pursued with a sense of urgency. Remaining a small public company is a poor outcome for shareholders due to the Company's microcap status and its high SG&A expenses, including management compensation and public-company costs, as a percentage of revenue. In addition to evaluating all options for creating shareholder value, the Company should also improve its corporate governance. We believe good corporate governance will lead to a better valuation for the stock as well as make SDPI more attractive to potential M&A partners."

08:36 EDT Masco announces $500M accelerated share repurchase - Masco announced it has entered into an accelerated share repurchase agreement with Wells Fargo Bank, National Association to repurchase $500 million of Masco's common stock. This agreement is part of Masco's existing share repurchase authorization under which $2 billion of authority was announced on February 9, 2021. Under the ASR agreement, Masco will receive initial delivery of approximately 7.9 million shares on May 10, 2022, representing approximately 85 percent of the number of shares of common stock initially underlying the ASR agreement, based on the closing price of Masco's common stock of $53.76 on May 9, 2022. The final number of shares to be repurchased will be based on Masco's volume-weighted average price during the term of the transaction, less a discount, and is expected to be completed no later than July 27

08:36 EDT UWM Holdings sees Q2 production in $26B-$33B range - With gain margin from 75 to 90 basis points.

08:35 EDT Celsion: Phase II GEN-1 study 85% enrolled, full enrollment seen in Q3 - Celsion Corporation provided an update on the progress made in the Company's two lead development programs. "We continue to make important progress in both of our lead development programs, and I am very pleased by the encouraging results to date," said Michael H. Tardugno, chairman, president and chief executive officer of Celsion. "Our PLACCINE DNA-based vaccine platform was recently highlighted at the 2022 World Vaccine Congress and is demonstrating its potential for rapid design and capability for targeting two or more different COVID variants in one vaccine. We have demonstrated a proof-of-concept utilizing a standard mouse model showing that PLACCINE can target two variants and produce robust levels of IgG, neutralizing antibodies, and t-cell responses. This proof-of-concept data is comparing favorably to commercial vaccines in mouse models with this data recently reported at the World Vaccine Congress. A vaccine that targets multiple strains at once and designed to provide long lasting immunity, is important in a future COVID-19 vaccination strategy. We are moving this program forward quickly and anticipate confirming our proof-of-concept in non-human primates over the next several months, with durability results later this year." Tardugno continued, "OVATION 2, the Phase II study of our GEN-1 immunotherapy in ovarian cancer is 85% enrolled. In spite of all of the challenges presented by COVID 19, we are hopeful to complete enrollment in the third quarter of this year. Preclinical and clinical data gives us every reason to believe in GEN-1's promise for ovarian cancer patients along with the support from leading medical researchers of the Gynecological Oncology Group. The GOG's interest in forging a partnership to develop GEN-1 in ovarian cancer will assist Celsion in its plans for an accelerated registrational program. Meanwhile, FDA has approved our protocol for a second Phase II clinical trial to evaluate GEN-1 in combination with Avastin in patients with advanced ovarian cancer. Our preclinical tumor inhibition data provides a convincing basis for this study. We look forward to initiating this study at major comprehensive cancer hospitals later this year."

08:34 EDT Sprinklr announces new CMO, Arun Pattabhiraman - Sprinklr announced that Arun Pattabhiraman has joined the company as its Chief Marketing Officer. Pattabhiraman brings extensive experience in B2B and B2C marketing with hyper-growth SaaS organizations. Most recently, Pattabhiraman was Chief Growth Officer at Freshworks, where he led a global team of 400+ marketing, operations, and sales development professionals and played a critical role in helping Freshworks become the first Indian B2B SaaS company to list on NASDAQ in September 2021.

08:33 EDT Prologis proposes to acquire Duke Realty in all-stock deal valued at $61.68 - Prologis (PLD) sent a letter to James Connor, Chairman and CEO of Duke Realty (DRE) proposing to acquire Duke Realty in an all-stock transaction. Under the terms of the proposal, Duke Realty stockholders would receive 0.466 shares of Prologis common stock for each share of Duke Realty common stock they own. Prologis' proposal is valued at $61.68 per Duke Realty share, based on Prologis' closing price on May 9, 2022, and represents a premium of 29% to Duke Realty's closing price on the same date. "We are confident that the proposed combination will be a win-win for our respective shareholders," said Prologis CEO and co-founder Hamid R. Moghadam. "Prologis has a proven track record serving as a leader and innovator in our industry. We are known for providing exceptional service to customers and delivering superior value for our shareholders, including the shareholders of companies we have merged with or acquired in the past. We have no doubt that Duke Realty's shareholders would similarly benefit from long-term value created by the combination of our companies."

08:30 EDT Prologis to acquire Duke Realty in all-stock deal valued at $61.68 per share

08:27 EDT Calix adds Constant Contact as out-of-the-box integration for Marketing Cloud - Calix continues to deliver on its promise to simplify and automate omnichannel marketing by launching an out-of-the-box integration between Constant Contact and Calix Marketing Cloud. Adoption of the Calix Revenue EDGE platform by broadband service providers has grown by more than 90 percent over the last year. Armed with the full platform, many BSPs are introducing breakthrough new services such as home-network security and connected cameras. Thanks to Marketing Cloud integrations with their favorite marketing automation solutions, it is easier than ever for BSPs to find and engage subscribers who might be interested in their new value proposition. Constant Contact is one of the top email marketing platforms for BSPs today. By incorporating real-time data and analytics from Marketing Cloud into their marketing campaigns, any BSP can easily target the right subscribers with the right message. This leads to better campaign response rates, revenue growth, and higher subscriber satisfaction. The latest Marketing Cloud integration adds to the growing ecosystem of solutions in the Revenue EDGE platform, which includes Mailchimp, Facebook, and HubSpot. Armed with these solutions, even a marketing team of one person can expand communications efficiency fourfold and engagement by 200 percent. The CommandIQ mobile app also makes it easy to communicate value to subscribers thanks to push notifications and subscriber alerts.

08:26 EDT Genoil completes bankable feasibility study for refinery project in Duqm Oman - Genoil announces that it has completed the bankable feasibility study for the planned refinery in Oman. The company is proceeding to finalize the project. Ras Madrakah owns the only private refinery license ever granted by the Government of Oman and project has received strong local support. Eight hundred hectares of land has been reserved for the project. Government gas supply is in place, there are three crude feedstock agreements in place for up to 200,000 barrels per day and three refined product offtake contracts have been secured as well. Eight square kilometers of land has been secured in the Special Economic Zone Authority of Duqm. The local licenses allow for export and import of products, sea and coastal oil and gas water transport and construction of petrochemical complexes. The local licenses have no limitation on project capacity and will allow for expansion in the future. The project will be very stimulative to the local economy and is estimated to create eighteen thousand jobs for the Sultanate of Oman and will utilize many existing contractors and local manufacturing vendors. It is expected that once the project is up and running it will be operated by Beijing Petrochemical and Yanchang Petroleum Limited.

08:23 EDT NetApp teams with Nvidia to accelerate HPC/AI supercomputing infrastructure - NetApp (NTAP) announced that NetApp EF600 all-flash NVMe storage combined with the BeeGFS parallel file system is now certified for NVIDIA (NVDA) DGX SuperPOD. The new certification simplifies artificial intelligence and high-performance computing infrastructure to enable faster implementation of these use cases. "The NetApp and NVIDIA alliance has delivered industry-leading innovation for years, and this new qualification for NVIDIA DGX SuperPOD builds on that momentum," said Phil Brotherton, Vice President of Solutions and Alliances at NetApp. "As performance and data demands are exploding, NVIDIA DGX SuperPOD, coupled with ONTAP AI platform and DGX Foundry AI service, ensures our customers get the best-in-class model training infrastructure, with the full support of AI industry leaders." "We're thrilled to be working with NetApp and NVIDIA to build an HPC/AI Center of Excellence with NVIDIA DGX systems so applied learning students can experience supercomputing and high-performance computing infrastructure," said Tonya Witherspoon, Associate Vice President, Industry Engagement & Applied Learning at Wichita State University. "NetApp is a digital fabric anchor of the innovation campus, and we can't wait to develop the next generation of talent in this exciting space."

08:22 EDT VYNE Therapeutics hosting KOL even on InhiBET BET Inhibitor Platform - VYNE Therapeutics announced that it will hold a virtual Key Opinion Leader, KOL, event on VYNE's InhiBET BET Inhibitor Platform on Tuesday, May 17, 2022 at 10:00 a.m. ET. The agenda for the webinar will include an overview on pan-bromodomain and extra-terminal inhibition for the treatment of various immuno-inflammatory conditions, a review of the current treatment landscape and unmet medical need in treating patients with vitiligo, a discussion of the preclinical data for VYNE's lead BET inhibitor, VYN201.

08:21 EDT Goosehead Insurance names Mark Miller as president and COO - Goosehead Insurance announced that Mark K. Miller, a current member of the Company's Board of Directors, has been appointed President and Chief Operating Officer effective today, May 10, 2022. Megan L. Bailey has been named Chief Sales Officer. In addition to her responsibilities overseeing Franchise Sales and Corporate Recruiting, she is now also leading the Company's Corporate Sales function. Michael Moxley has been named Chief Service Officer responsible for Service, IT and Risk Management. P. Ryan Langston has been named Chief Legal Officer responsible for all legal, compliance, human resources and real estate functions. Michael Colby, former President and COO, has left the company to pursue other endeavors.

08:20 EDT ProPhase Labs names Bill White as CFO, effective May 23 - ProPhase Labs (PRPH) announced that Bill White has been appointed CFO of ProPhase Labs, effective May 23, 2022. White joins ProPhase Labs from Intellicheck (IDN), where he served as CFO, Treasurer and Secretary since April 2012 and COO since March 2020.

08:19 EDT Teva publishes 2021 ESG Progess Report - Teva Pharmaceutical Industries published its 2021 ESG Progress Report today. The report details how Teva further integrated ESG into its business strategy-implementing a strengthened ESG governance structure and setting 13 ambitious targets related to access to medicines, ethics, environment and responsible supply chain, some of which are now linked to the company's financing strategy and executive compensation. "As one of the world's largest manufacturers of generic medicines, ESG is integral to the long-term strategy of our company and is part of everything we do," said Kundefinedre Schultz, President & CEO of Teva. "Our ESG Progress Report details our actions in 2021, which include issuing a $5 billion sustainability-linked bond, tying our financing strategy to access to medicines and environmental targets. We are in a unique position to help create a healthier future, bringing our essential medicines within reach for more people and reinforcing business integrity through our compliance and ethics policies and trainings." This year's ESG Progress Report offers a comprehensive view of ESG at Teva, with new disclosures related to scope 3 emissions, pay equity and the company's responsible supply chain, and continues to align with leading reporting standards-the Global Reporting Initiative, Sustainability Accounting Standards Board and Task Force on Climate-Related Financial Disclosures.

08:18 EDT Spirent unveils new security automation package for 5G Core test suite - Spirent Communications announced a new security automation package as part of the 5G Core Automation Platform for Spirent Landslide. The new security package expands on the industry's first subscription-based automated test platform launched by Spirent in 2021 and is equipped with a unique pre-built security test library. The new package enables service providers to accelerate time-to-market by up to 60% and achieve cost savings of up to 80%. The open cloud-based architecture of 5G introduces the potential for new security vulnerabilities that must be secured to support the mission-critical use cases being promised by 5G. Spirent's new security automation package for Landslide combines the company's proven test methodology, automation, and 5G and security expertise into a single pre-built solution that service providers can plug into their automation pipelines.

08:17 EDT INmune Bio presents data on effects of tumor necrosis factor in MS - Inmune Bio announced that Professor Lesley Probert Ph.D., head of the department of Immunology at the Hellenic Pasteur Institute in Athens, Greece will be presenting data on the effects of tumor necrosis factor in MS at the 3rd European Conference on Neuroinflammation concluding in London today. The data presented today show that XProTM also promotes remyelination within the gray matter of the brain by inducing the brains natural repair mechanisms. Neutralization of soluble TNF with XProTM activates pro-microglial and pro-astroglial responses to clear degenerated myelin and promote remyelination in cortical areas.

08:16 EDT SpartanNash, DoorDash partner for on-demand grocery offerings - SpartanNash announced an innovative partnership with local commerce platform DoorDash to expand the Company's grocery services and solutions across both digital and physical platforms through various different initiatives. DoorDash is partnering with SpartanNash to offer on-demand grocery delivery from more than 100 SpartanNash owned stores including Family Fare, Martin's Super Markets and more. The partnership will also include the opportunity for SpartanNash's network of 2,100 independent retail customers to leverage both the DoorDash marketplace app and website as well as DoorDash Drive, the white-label fulfillment platform that powers direct delivery for businesses, to address their local commerce needs and offer on-demand grocery delivery to consumers in their communities. As part of the omni-channel partnership, SpartanNash will also serve as a distributor of pantry and household items to DoorDash DashMart locations beginning in New York City with plans to scale to additional locations in the future.

08:16 EDT Applied Blockchain expands blockchain industry infrastructure - Applied Blockchain celebrated the formal opening of its 100-megawatt, MW, hosting facility in Jamestown, North Dakota. The facility currently has 83MW online, with the remainder scheduled to come online during the second calendar quarter of 2022. The new 100MW facility follows Applied Blockchain's recent initial public offering with its common stock listing on the Nasdaq Global Select Market under the symbol "APLD." "As part of our commitment to advance the blockchain movement and further propel digital transformation opportunities for global enterprises and the financial industry, the new 100MW facility is ready to provide power to the blockchain infrastructure," said Wes Cummins, CEO of Applied Blockchain. "The community of Jamestown and representatives of North Dakota have been outstanding to work with as we brought this state-of-the-art facility to life. In collaboration with our dedicated team, Applied Blockchain is now able to support and service more customers than ever before."

08:14 EDT Deluxe teams with with Codat to embed accounting integrations into payroll/HR - Deluxe announced a relationship with Codat, the universal API for small business data that provides connectivity to mid- and large-sized clients to build integrated products for SMBs. Through this effort, Deluxe Payroll + HR Solutions customers will now be able to reconcile their accounting data back into their accounting software automatically. The first accounting software immediately available for set-up is QuickBooks Online QBO. Seamless in-platform integration to a business's accounting software is not common with payroll providers today. Historically, owners of small- and medium-sized businesses using accounting software, such as QuickBooks, had to export their payroll data from their current payroll provider's platform, and then manually import it into their accounting software. Using Codat's API, Deluxe is providing a white-labeled solution, connecting a QBO account directly to the Deluxe Payroll + HR Solutions account, enabling automatic data reconciliation. Through this relationship, business owners will connect once on the Deluxe platform and, using Codat's technology, the ongoing synchronization is managed seamlessly in the background. The automation of this manual process will save business owners time, reduce errors, and ultimately ensure payroll data accuracy.

08:13 EDT Infinera's ICE6 Solution selected by AAE-1 Consortium - Infinera announced that the Asia-Africa-Europe-1, AAE-1, Consortium, owner of one of the largest consortium cable systems in the world, selected Infinera's ICE6 coherent 800G solution to increase its submarine network capacity and provide "diverse, resilient connectivity across European, Asian, African, and Middle Eastern markets," the company said. AAE-1's submarine upgrade will more than double the current capacity, providing in excess of 100 Tb/s, resulting in the largest-scale submarine upgrade in history. AAE-1's cable system spans 25,000 kilometers of submarine and terrestrial networks, connecting 19 countries led by a consortium of 19 leading operators. By upgrading with Infinera's fifth-generation ICE6 technology on the GX Series Compact Modular Platform, AAE-1 is able to "leverage the industry-leading submarine optical network solution that features the highest level of spectral efficiency, long-codeword probabilistic constellation shaping, Nyquist subcarriers, and the ability to seamlessly upgrade its line system to enable L-band transponders on some of its terrestrial network segments," the company said.

08:13 EDT Endra Life Sciences issued additional patents for TAEUS System - ENDRA Life Sciencesannounces the issuance of four new patents, two in the U.S. and two in China. ENDRA's intellectual property portfolio now includes 90 assets, including 46 issued patents worldwide providing protection for the TAEUS system with its novel hybrid ultrasound and thermoacoustic imaging technology. One of the newly issued U.S. patents, which protects the ability to transfer data without an internet connection, expands potential licensing opportunities for the company. The following four patents, strengthening the TAEUS system's proprietary position, were issued: U.S. Patent No. 11314617, titled "Methods and Systems for Exchange of Equipment Performance Data," is ENDRA's first patent that protects its proprietary method and system for acquiring, analyzing, and sharing data in the cloud. Although this technology was developed for the TAEUS system, it has broad applicability within the healthcare industry and as such, represents an additional licensing opportunity. The company has filed another application to complement the '617 patent, which is expected to form the keystone of a patent family. U.S. Patent No. 11304606, titled "Method and System for Enhancing RF Energy Delivery During Thermoacoustic Imaging," relates to optimizing the thermoacoustic energy source, a radiofrequency emitter, to provide a stronger and clearer signal that improves thermoacoustic measurements. Chinese Patent No. ZL 2019 8 00868104, titled "Method and System for Monitoring Tissue Temperature," relates to a novel method and system for monitoring tissue temperature during surgical procedures. ENDRA expects its TAEUS system to be effective for both thermotherapy and cryotherapy procedures. The '104 patent is linked to its parent, U.S. Patent No. 10631734B1. Chinese Patent No. ZL 2019 8 00859567, titled "Method and System for Estimating Fractional Fat Content of an Object of Interest," relates to a novel method for determining the fractional fat content of an object, such as a person's liver. This method utilizes a radiofrequency applicator that is a critical component of the TAEUS system. The '567 patent is linked to its parent, U.S. Patent No. 11051699B2.

08:12 EDT Cortexyme expands pipeline with Novosteo acquisition, no terms - Cortexyme announced that it entered into an agreement under which the company plans to acquire Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury. Upon completion of the transaction, Novosteo stockholders will own approximately 15.5% of the combined company. The transaction, which has been approved by the Boards of Directors of both companies, is expected to close within the next 30 days. David Lamond, chairman of Cortexyme's Board of Directors, said, Dr. Dirk Thye, chief executive officer of Novosteo, commented, "We have assembled a highly experienced and impressive team to aggressively pursue the company's next stage of growth. We intend to capitalize on the combined assets of Novosteo and Cortexyme by driving our therapeutic candidates through development, expanding our targeted drug..Upon the close of the acquisition, the company will appoint Novosteo executives Dr. Dirk Thye as chief executive officer, and Dr. Karen Smith as chief medical officer of Cortexyme, adding experienced leadership to support its next stage of growth. Dr. Dirk Thye and Philip Low, PhD, a current director of Novosteo, will also join the company's Board of Directors upon close of the transaction. The company also plans to operate under a new name - Quince Therapeutics . - and begin trading under the ticker symbol "QNCX" in the coming months. At that time, the company will present an overview of its pipeline development plans, clinical activity updates, and anticipated milestones. The acquisition of Novosteo reflects the strategic expansion of our pipeline, which remains focused on bringing innovative therapeutics to diseases with high unmet clinical needs," said Chris Lowe, Cortexyme's interim chief executive officer. "We are excited about the addition of Novosteo's targeted therapy platform and extensive preclinical data to our expanding therapeutic pipeline. I believe the appointments of Dr. Dirk Thye as CEO and Dr. Karen Smith as CMO will bring exceptional expertise to lead the company."

08:10 EDT Reservoir Media announces deal with Mohamed Ramadan, purchase of 100COPIES - Reservoir Media, in conjunction with PopArabia, announced two new deals as the company continues to execute on its emerging markets growth strategy. The deals include the signing of Egyptian rapper and singer Mohamed Ramadan to a worldwide publishing deal, which includes hits from his catalog and future releases. Reservoir and PopArabia separately announced the acquisition of Egyptian label 100COPIES, as well as a joint venture with the company to sign and develop Egyptian talent.

08:09 EDT L.B. Foster sees funding operations in 2022 and beyond - The company said: "During the 2022 first quarter, the Company's backlog grew by $34.4 million, finishing at a robust at $244.6 million. The Company is maintaining its optimistic outlook regarding the longer-term trends in its core end markets of freight and transit rail and general infrastructure. While overall quotation activity and demand in these markets continues to improve, they are still below pre-pandemic levels, particularly in its rail markets. The Company expects that many of its businesses will continue to directly benefit from infrastructure investment activity, including funding benefits from U.S. Infrastructure Investment and Jobs Act passed in November 2021. While order and backlog levels in our Precast business have benefited from the Great American Outdoors Act passed in 2020, we have not yet seen significant business activity from the IIJA. We believe IIJA-related funding will be processed by the various agencies during 2022. We should then see our quotations and orders increasing as we progress through the year, with related revenue realized in 2023 and beyond. The present inflationary environment in labor and raw materials continues to pressure margins across the business, and the Company has taken and will continue to take pricing actions where possible to help mitigate such impacts. In addition, the Company continues to take proactive steps to manage disruptions in raw materials, labor, supply chains, service partner resources, and lingering COVID-19 related effects to mitigate their adverse impact on its operations and results as much as possible. While such conditions and the related impacts are expected to improve in 2022, they could persist throughout 2022 and possibility longer. Despite these challenges, with the proceeds from the Piling division divestiture coupled with the additional flexibility and capacity resulting from the amendment and extension of our credit agreement completed in August 2021, the Company believes it has the resources available to fund its operations and execute on organic and acquisitive growth opportunities in 2022 and beyond."

08:07 EDT Fox Corp. reports Q3 affiliate revenues increased 5% - The company reported total quarterly revenues of $3.46B, a 7% increase from the $3.22B reported in the prior year quarter. Affiliate revenues increased 5% with 8% growth at the Television segment and 3% growth at the Cable Network Programming segment. Advertising revenues increased 9%, primarily due to stronger pricing and higher ratings at FOX News Media and continued growth at Tubi. Other revenues increased 18%, driven by the timing of sports sublicensing revenues at the Cable Network Programming segment, which were impacted by Coronavirus Disease 2019 in the prior year quarter, and the impact of the consolidation of entertainment production companies at the Television segment. Commenting on the results, Executive Chair and CEO Lachlan Murdoch said: "FOX's third quarter results again demonstrate our capacity to deliver sustained and consistently strong revenue growth. Our 7% topline growth in the quarter was propelled by pricing strength in both distribution and advertising revenues across our leadership brands, complemented by the powerful momentum we continue to see at Tubi. In the three years since the formation of FOX we have seen rapid industry change. Our focused portfolio and clear strategy underpin our success today and continue to distinguish FOX from its peers. The power of our brands and the scaled audiences that they serve continue to provide a uniquely strong platform to strategically manage our businesses for long-term growth in a thoughtful and disciplined manner."

08:06 EDT United Airlines signs international PA for sustainable aviation fuel - United, which has invested in more sustainable fuel production than any other airline in the world, became the first U.S. airline to sign an international purchase agreement for sustainable aviation fuel. The airline has signed a new purchase agreement with Neste that provides United the right to buy up to 52.5M gallons over the next three years for United flights at Amsterdam's Schiphol Airport, and potentially other airports as well. Neste will provide United with 2.5M gallons of SAF in Amsterdam in the first year. United will also have the right to purchase up to 20M gallons in the second year, and up to 30 million gallons in the third year, at Amsterdam or other locations that Neste can supply throughout the globe, as Neste increases its SAF production. This supply agreement is enabled by Neste's ambitious growth strategy, which will see the company producing 515M gallons of SAF per year by the end of 2023. Neste has been producing and delivering SAF since 2011 and has a proven track record of supplying SAF to customers in Europe, Asia and the Americas.

08:04 EDT Prelude Therapeutics sees cash, eqiuvalents funding operations into 2H24

08:03 EDT Incannex reports data from IHL-216A preclinical study - Incannex Healthcare announced that IHL-216A was observed to have a strong neuroprotective effect in a widely known model of sports concussion. The preclinical study compared IHL-216A to its component drugs, cannabidiol, or CBD, and isoflurane, in a rodent model of sports concussion that was developed in collaboration with the US National Football League, or NFL, to accurately represent the type of brain injury that occurs in sports related concussion. This study compared six groups of twenty-four Sprague Dawley rats. When animals were tested in a Y-maze task, which assesses spatial memory by determining the animal's ability to discriminate between a novel (new) and familiar arm, twenty-four hours after injury, animals treated with IHL-216A were found to have no difference in discrimination index compared to sham animals. In contrast, injured animals treated with either vehicle or isoflurane alone after injury, the discrimination index was significantly reduced compared to sham animals. The group treated with CBD alone had intermediate performance in the Y-maze between sham and vehicle treated animals. These findings indicate that the defect in spatial memory observed at 1 day post injury is restored in animals treated with IHL-216A. The study was conducted at the Department of Neuroscience, Monash University.

07:59 EDT II-VI unveils node-on-a-blade platform - II-VI Incorporated unveiled its node-on-a-blade platform, a scalable multi-degree reconfigurable optical add-drop multiplexer, ROADM, system. The system embeds ultrahigh-resolution telemetry that is critical for high-mix wavelength services, and compact wavelength selective switch, WSS, technology that is ideal for enterprise access networks. "Our broad portfolio of optical technologies for ROADM networks is the most complete, highly differentiated, and often the first on the market," said Dr. Richard Smart, Senior Vice President, ROADM Business Unit. "This enables us to form close relationships with customers who are looking to deploy disruptive optical networking solutions."

07:57 EDT Emerita says fully permitted to execute on drill program for La Romanera - Emerita Resources announces that further to its April 5, 2022 press release, the Territorial Delegation of Sustainable Development of Huelva of the Regional Government of Andalusia granted Emerita the Unified Environmental Authorization in respect of the La Romanera and El Cura deposits at the company's wholly-owned Iberia Belt West Project. The company is now fully permitted to execute on its drill program at the La Romanera and El Cura deposits and drilling is commencing as soon as set up is completed, Emerita stated.

07:55 EDT Discover publishes 2021 corporate responsibility report - Discover published its 2021 Corporate Responsibility Report Building a Brighter Tomorrow, which shares actions the company undertook in fulfilling its mission to help people achieve brighter financial futures. From providing free financial education curriculum to thousands of classrooms across the country, operating responsibly, and protecting the environment to bringing new jobs and economic opportunities on Chicago's South Side, the report highlights Discover's efforts in improving the financial stability and well-being of its customers, employees, and communities. Earlier this year, the Company released its first Diversity, Equity & Inclusion Transparency Report, named Johanson as Chief ESG Officer, and published an ESG-focused tear sheet which includes an ESG mission statement and initial environmental disclosures.

07:54 EDT Rallybio announces in-licensing of Sanofi's KY1066 - Rallybio Corporation announced that it has obtained worldwide exclusive rights to Sanofi's KY1066, which will be referred to as RLYB331 going forward, a preclinical potentially first-in-class antibody. RLYB331 has the potential to address a significant unmet need for patients with severe anemia with ineffective erythropoiesis and iron overload, such as beta thalassemia and a subset of myelodysplastic syndromes, amongst others. The transaction expands Rallybio's pipeline, is strategically consistent with Rallybio's existing focus on hematology, and aligns with its mission to accelerate the development of life-transforming therapies for patients with severe and rare disorders. RLYB331 is a monoclonal antibody that inhibits Matriptase-2. The inhibition of MTP-2 significantly increases levels of hepcidin, decreases iron load and treats ineffective erythropoiesis. The standard of care for many such hematological disorders leaves a significant unmet need in iron overload associated anemias with patients experiencing significant morbidity and consequent mortality. Rallybio plans to prosecute preclinical activities for RLYB331 including CMC, and dose-range finding and toxicity studies, which will then support transition of the asset into clinical development. Under the terms of the license agreement, Rallybio will make an upfront cash payment of $3 million to Sanofi, in addition to development and commercial milestones, and mid to high single digit royalties on net sales.

07:53 EDT Neximmune appoints Gandhi to board of directors - NexImmune announced the appointment of Leena Gandhi, M.D., Ph.D., Director for the Center of Therapeutic Innovation at Dana-Farber Cancer Institute, to its Board of Directors as a Non-Executive Director.

07:52 EDT Evaxion Biotech reports successful production of personalized immunotherapies - Evaxion Biotech announced that it has successfully produced all batches of personalized cancer immunotherapies for all patients enrolled in the Phase 1/2a clinical trial of EVX-02 in adjuvant melanoma. Birgitte Rono, Chief Scientific Officer of Evaxion, said: "I am extremely proud that the team behind EVX-02 has shown that this complex production chain is feasible and that we can provide truly unique, personalized DNA vaccines within a critical time window. And we are delighted that we mastered all steps in the production process. Every cancer is unique, as is every immune system, and this is why we create cancer therapies that are one size fits one - and only one." This is the second time Evaxion has conducted a clinical trial with personalized cancer immunotherapy, having previously used a peptide-based treatment.

07:52 EDT Nextech AR Solutions to voluntarily delist from the NEO - Nextech AR Solutions has submitted a request to voluntarily delist its common shares from the NEO Exchange to reduce the associated cost of being listed on multiple exchanges in Canada. The Company's Common Shares will remain listed on the Canadian Securities Exchange under the trading symbol: NTAR and the OTCQB: NEXCF, the same stock symbols. The Common Shares are expected to be delisted from the NEO at close of business on Thursday, May 12, 2022. No action is required by shareholders.

07:50 EDT CI Financial unit applies for charter to establish trust company CI Trust - CI Private Wealth US a subsidiary of CI Financial announced that it has applied for a charter to establish and operate a South Dakota trust company CI Trust . Once chartered, CI Trust will offer administrative trust solutions to clients through CIPW's national wealth management platform. "CI Trust will allow us to offer clients a variety of robust trust solutions and further enhance the elite client experience that CI Private Wealth provides," said Kurt MacAlpine, Chief Executive Officer of CI. "Trusts are a critical part of meeting the complex wealth management and estate planning needs of ultra-high-net-worth and high-net-worth clients. CI Trust will offer comprehensive, customized administrative trust solutions designed to satisfy each client's goals, while CIPW manages the trust's assets to ensure alignment with the client's overall wealth management plan." CI entered the U.S. registered investment advisor sector in January 2020 and quickly became one of the fastest-growing wealth management firms in the U.S. Once all outstanding acquisitions are completed, CI's U.S. assets will reach approximately US$134B.

07:47 EDT KREST 's investments add $234M of diversified real estate debt exposure - KKR, a leading global investment firm, today announced that KKR Real Estate Select Trust KREST or the has completed four real estate debt investments with a combined value of $234 million. The transactions grow the Fund's portfolio allocation to income-focused real estate debt investments to approximately 28 percent as of March 31, 2022. The new debt investments are estimated to have a weighted average yield in the first year of ownership of approximately 8.6 percent. The debt investments are primarily floating rate and backed by diversified high quality, stabilized commercial real estate. Underlying exposures include: The Old Post Office, a newly redeveloped landmark commercial office building in Chicago; the American Copper Buildings, a pair of luxury multifamily towers in New York City; and two large select service U.S. hotel portfolios with high quality sponsorship. "We are pleased to grow KREST's exposure to real estate debt with four new investments that are representative of KKR's strategy of investing in loans backed by high quality real estate owned by institutional sponsors and aligned with our long-term thematic convictions," said Matt Salem, KKR Partner and Head of Real Estate Credit. "We believe that Class A office space, lifestyle-oriented multifamily and room-only lodging catering to domestic travel are attractive and resilient categories positioned to benefit from long-term tailwinds."

07:45 EDT Sensei Biotherapeutics sees cash balance funding operations into 1Q25 - Cash, cash equivalents and marketable securities were $136.2 million as of March 31, 2022, as compared to $147.6 as of December 31, 2021. Sensei expects the current cash balance to fund operations into the first quarter of 2025.

07:44 EDT EVgo selected as EV charging network provider for Portland, Maine - EVgo announced that it was selected as the City of Portland's partner to deploy electric vehicle charging infrastructure on city-owned property. Through the partnership, EVgo will install eight direct current fast chargers and up to 44 Level 2 chargers across Portland, Maine.

07:42 EDT Frontier Communications prices $1.2B of first lien secured notes - Frontier Communications Holdings announced the pricing of its previously announced private offering of $1.2 billion aggregate principal amount of first lien secured notes due 2030. The Notes will bear interest at 8.750% per year and will be sold at a price equal to 100% of the aggregate principal amount. The Notes offering is expected to close on May 12, 2022, subject to customary conditions. Frontier intends to use the net proceeds of the offering to fund capital investments and operating costs arising from the company's fiber build and expansion of its fiber customer base, and for general corporate purposes. Frontier also announced an increase to its senior secured first lien revolving credit facility by an additional $275 million, to a total of $900 million in aggregate principal amount of revolving credit commitments. The Revolving Facility was also amended to reflect SOFR based interest rates.

07:42 EDT Agrify announces multimillion dollar engagement with Boone Labs - Agrify announced it has signed a definitive agreement to provide Boone Labs, a Buchanan, Michigan-based vertically integrated cannabis operator, with a broad range of cultivation and extraction solutions at its new production facility. Under the terms of the Agreement, which is valued at $2M, approximately $1.5M will go towards Vertical Farming Units, VFUs, and $0.5M will go towards a full range of extraction systems. Agrify expects to supply Boone Labs with a comprehensive lineup of the services and equipment necessary to launch a highly successful cannabis production facility. The Agreement consists of facility design services, industry-leading cultivation, extraction, distillation, isolation, and lab equipment, proven recipes and operating procedures for growing consistently high-quality flower and creating connoisseur-grade extracts, as well as the most advanced and intuitive automation and production-planning software.

07:41 EDT Oncorus appoints Richard Wanstall as CFO - Oncorus (ONCR) announced the appointment of Richard Wanstall as Chief Financial Officer, CFO. Most recently, Wanstall served as Chief Financial Officer and Treasurer for Aileron Therapeutic (ALRN), where he was responsible for overseeing the company's strategy, finance, investor relations, and operations activities.

07:39 EDT Summit Materials appoints Kekin Ghelani Chief Strategy and Growth Officer - Summit Materials appointed Kekin Ghelani as the Company's first-ever Chief Strategy and Growth Officer. Previously Kekin was Vice President of Strategy, Growth and Ventures for the Water & Protection of DuPont de Nemours, Inc. and held senior positions at Celanese, McKesson, and Honeywell. He holds an MBA from Emory University.

07:38 EDT Seres Therapeutics to present data on SER-108 at DDW meeting - Seres Therapeutics announced that it will present data from its ECOSPOR III trial of SER-109 at the Digestive Disease Week Annual Meeting, which is taking place May 21-24, 2022. SER-109 is an investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection. With an oral and poster presentation, Seres will present data on how SER-109 restores the functionality of the microbiome in a rapid and durable manner, which further supports the potential of microbiome therapeutics. Seres expects to finalize a Biologics License Application submission for SER-109 with the U.S. Food and Drug Administration in mid-2022. "We are eager to showcase new data that further validate the potential of our investigational microbiome therapeutic, SER-109, at the world's largest gathering of physicians and researchers in the digestive disease field," said Lisa von Moltke, M.D., Chief Medical Officer at Seres. "These data reinforce our strongly-held belief in the power of the microbiome, and we are hopeful of delivering the first-ever FDA-approved microbiome therapeutic, a potentially transformative treatment option to patients in need."

07:37 EDT Marimaca Copper reports results from 10 RC drill holes - Marimaca Copper Corp. announced results from a further ten reverse circulation drill holes, totaling 3,320m, from the 2022 infill drilling campaign at the Marimaca Oxide Deposit. The drilling intersected broad zones of near-surface green copper oxide mineralization in all holes. As with the first infill results, these holes confirmed the mineralized zones as interpreted in the existing Mineral Resource Estimate area for the MOD, but with several zones encountering higher grades than expected. Furthermore, several intercepts were extensional, falling outside the 2019 MRE block model, with positive implications for future resource updates. There is also evidence of extensions to the recently discovered MAMIX zone, the company said in a statement.

07:36 EDT Castle Biosciences teams with The Sun Bus to provide free skin cancer tests - Castle Biosciences announced that for the second year, it is a national sponsor of The Sun Bus, a mobile clinic that provides free skin checks and sun safety education across numerous U.S. states. "Skin cancer is the most commonly diagnosed cancer in the U.S.," said Tamara Terzian, Ph.D., executive director of The Sun Bus, "so it is important that people know how to protect their skin and are aware of the need to perform periodic skin checks. The Sun Bus allows us to take this important message on the road and share it with thousands of people on our tours each year." The Sun Bus plans to provide over 360 hours of free skin screening services and sun safety education at more than 50 locations across Texas, Georgia, Iowa, Kansas, Missouri, Wyoming, Colorado, New Mexico and Arizona during its expanded and extended 2022 tour. This includes a stop at Castle's headquarters in Friendswood, Texas, on Monday, May 16. "At Castle, we are passionate about improving patient care, and that begins first with education and awareness around the importance of prevention and the early detection of skin cancer," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "The Sun Bus makes getting a skin cancer screening from a medical professional possible for many who may not otherwise have the opportunity, and we are proud to be a major national sponsor of their mobile clinic."

07:35 EDT Selina appoints Eyal Amzallag as COO - Selina announced that it has appointed veteran hospitality executive Eyal Amzallag as CEOO. In this role, Amzallag reports to Selina's co-founder and CEO, Rafael Museri, and is responsible for overseeing the operations of Selina's growing portfolio of hotels, which includes 150 open or secured properties across 25 countries and six continents. In this role, he will help ensure that each Selina location delivers on the evolving needs of the company's rapidly expanding and loyal community of digital nomads.Amzallag brings to Selina a wealth of relevant on-property and managerial experience, having progressed through the ranks at Club Med over the past two decades. Most recently, Amzallag served as Managing Director South Europe, Middle East & Emerging Markets.

07:30 EDT Immatics initiates Phase 1 trial to evaluate IMA401 in advanced solid tumors - Immatics N.V. announced the initiation of a Phase 1 clinical trial with its T cell engaging receptor IMA401 for patients with recurrent and/or refractory solid tumors. IMA401 is the most advanced product candidate from Immatics' TCR Bispecific pipeline targeting an HLA-A*02-presented peptide derived from both MAGEA4 and MAGEA8. TCER(R) IMA401 will be developed in collaboration with Bristol Myers Squibb. Immatics is responsible for conducting the Phase 1 clinical trial. The primary objectives of the clinical trial are to determine the maximum tolerated dose and/or the recommended phase 2 dose for IMA401 in biomarker-positive patients with recurrent and/or refractory solid tumors. Secondary objectives are to characterize safety and tolerability, evaluate initial anti-tumor activity and assess pharmacokinetics of IMA401. The Phase 1 trial consists of a dose-escalation portion that will be followed by a dose-expansion portion to treat patients at the recommended dose level. The trial is planned to be conducted at up to 15 centers in Germany, with the first site already being initiated. The Phase 1 trial is designed to enroll approximately 50 patients.

07:29 EDT AdaptHealth board authorizes $200M share repurchase program - The Company announced that its Board of Directors has authorized a share repurchase program for up to $200 million of the Company's common stock through December 31, 2022. The timing and actual number of shares to be repurchased will depend upon market conditions and other factors. Shares may be repurchased from time to time on the open market, through privately negotiated transactions or otherwise. Purchases may be started or stopped at any time without prior notice depending on market conditions and other factors. The Company intends to fund the share repurchase program through its available cash and liquidity.

07:27 EDT Compugen announces departure of CFO/COO Ari Krashin - Compugen announced that Ari Krashin, CFO and COO, notified the company of his wish to depart from his position to pursue other interests. Krashin will leave in August 2022 and, until his departure, he will continue to support the company in his current roles. The departure is not related to any matter connected with the company's operations, policies or practices.

07:25 EDT Dream Finders maintains guidance of minimum 7,000 home closings in FY22 - Dream Finders Homes maintains its guidance of a minimum of 7,000 home closings for the full year 2022. Any further COVID-19 governmental restrictions on land development, home construction or home sales or additional supply chain challenges could negatively impact the Company's ability to achieve this number of home closings in 2022. As of March 31, 2022, the Company backlog was 7,413 homes, with approximately 20.0% of the homes in backlog expected to be delivered in 2023 and beyond. The Company continues to believe the backlog of homes sold is the best indicator for future growth. The following table shows the backlog units and ASP as of March 31, 2022 by segment:

07:22 EDT Athenex plans to extend cash runway into 2023 - As of March 31, 2022, the company had cash and cash equivalents of $27.2 million, restricted cash of $13.8 million, and short-term investments of $10.2 million, for a total of $51.2 million. The company is implementing cost savings programs and monetizing non-core assets, and as the company completes such activities, the company plans to extend its cash runway into next year.

07:19 EDT Stoke Therapeutics expects cash to fund operations into 2025 - As of March 31, 2022, Stoke had approximately $293.8 million in cash, cash equivalents, marketable securities and restricted cash, which is anticipated to fund operations into 2025.

07:17 EDT Achilles Therapeutics expects cash to fund operations into 2H of 2024 - Cash and cash equivalents: Cash and cash equivalents were $236.9 million as of March 31, 2022, as compared to $266.3 million as of December 31, 2021. The Company anticipates that its cash and cash equivalents are sufficient to fund its planned operations into the second half of 2024, including full funding of the ongoing Phase I/IIa CHIRON and THETIS clinical trials.

07:17 EDT Achilles Therapeutics announces upcoming milestones - Higher-dose Monotherapy: Report initial data from the higher-dose cohort of patients undergoing cNeT monotherapy for the treatment of NSCLC and melanoma in the second half of 2022. cNeT Combination: Dose first melanoma patient with cNeT in combination with a PD-1 checkpoint inhibitor in Cohort B of the THETIS clinical trial and report initial data in the second half of 2022. Manufacturing: Begin clinical cNeT production at the Cell & Gene Therapy Catapult facility in the second half of 2022. Tumor Archiving Program: Initiate program in the second quarter of 2022.

07:16 EDT TransDigm says 2022 guidance 'remains suspended' - "The company's full fiscal 2022 guidance remains suspended at this time as a result of the continued disruption in our primary commercial end markets."

07:14 EDT Norwegian Cruise Line taking 'proactive measures' to enhance liquidity - The Company's monthly average cash burn for the first quarter of 2022 was approximately $375 million, below the prior estimate of approximately $390 million. This cash burn rate does not include cash inflows from bookings or contribution from ships that re-entered service. Beginning in April 2022, the Company resumed debt amortization payments which were deferred during the pandemic.

07:13 EDT CECO Environmental announces $20M share repurchase program - CECO Environmental announced that its Board of Directors has authorized a share repurchase program under which CECO may repurchase up to $20M of its outstanding shares of common stock through April 30, 2025.

07:12 EDT Diversey reaffirms FY22 adjusted EBITDA view $380M-$420M - Reaffirms 2022 Adjusted EBITDA outlook to range from $380 to $420 million with full year revenue growth of high single digits.

07:06 EDT Peloton to borrow $750M in 5-year term debt, says CEO - Peloton (PTON) CEO Barry McCarthy said: "We finished the quarter with $879 million in unrestricted cash and cash equivalents, which leaves us thinly capitalized for a business of our scale. Earlier this week we took steps to strengthen our balance sheet by signing a binding commitment letter with JP Morgan (JPM) and Goldman Sachs (GS) to borrow $750 million in 5-year term debt. I want to thank everyone involved for their hard work in completing this important financing and look forward to reporting on our progress in reshaping Peloton's business in the quarters ahead. As we begin to sell down our excess inventory, the current cash flow headwind should become a tailwind in FY23. Our goal is to restore the business to positive free cash flow in FY23."

07:05 EDT Peloton goal is to become global fitness platform with 100M members - CEO and President Barry McCarthy said: "My goal for Peloton is to become a global connected fitness platform with 100 million Members. That's equivalent to roughly half the world's global gym memberships. It's a long, long way from where we sit today. But we sit at the epicenter of technology enabled fitness, a long-term secular growth trend. Who doesn't want to live a healthier, happier, longer life? We will share more about how we plan to participate in that growth in the months and years ahead."

07:03 EDT GFL Environmental authorizes share repurchase program - GFL Environmental announced that the Toronto Stock Exchange has accepted the Company's notice of intention to implement a normal course issuer bid during the 12-month period commencing on May 12, 2022 and ending no later than May 11, 2023. The NCIB will be conducted through the facilities of the TSX and the New York Stock Exchange or alternative Canadian trading systems, if eligible. On May 6, 2022, GFL had 330,213,882 subordinate voting shares issued and outstanding. Under the NCIB, a maximum of 16,510,694 subordinate voting shares may be repurchased by GFL. All subordinate voting shares repurchased by GFL under the NCIB will be cancelled.

07:00 EDT US Foods announces transition of CEO Pietro Satriano, affirms FY22 guidance - The company states: "The US Foods Board announced that Pietro Satriano, Chief Executive Officer, is leaving the Company and will not stand for re-election as director at the upcoming 2022 annual meeting of shareholders. Robert M. Dutkowsky has been appointed Executive Chair and Andrew Iacobucci has been appointed Interim Chief Executive Officer. Dutkowsky currently serves as non-executive Chairman of the Board and Iacobucci currently serves as Chief Commercial Officer. To identify a permanent CEO, the Board has formed a five-member search committee. The company reaffirms the fiscal year 2022 guidance provided on February 17, 2022."

06:59 EDT ReNew Power appoints Kadar Upadhye as Group CFO - ReNew Power announced it has hired a Group CFO to help drive its next phase of strong growth. ReNew has also hired a new General Counsel and a Chief Growth Officer who will help lead the company's expansion journey over the next decade, including its push into new clean energy segments such as green hydrogen. The leadership hires come as ReNew's gross total portfolio jumped nearly 20% to ~12.1 GW at the end of April from 10.2 GW at the beginning of 2022. ReNew continues to lead the industry as India's top utility-scale solar developer in 2021, according to Mercom India. Kedar Upadhye has been appointed as Group CFO. He comes with over 22 years of diverse and global experience. Prior to joining ReNew, he was President and Global CFO, Cipla. Vikash Jain joins ReNew as Global General Counsel. He comes with rich and varied international experience of over 26 years in compliance, governance, and litigation. In his last role, he was Group General Counsel for Vedanta Resources Limited, which included being General Counsel for Cairn Oil & Gas. ikram Kapur, with over two decades of professional experience, joins in the newly created Chief Growth Officer role to help build new businesses such as green hydrogen and carbon markets, as well as international partnerships to enable the core and nascent businesses. Prior to joining ReNew, he spent 17 years at McKinsey & Company, where he was a senior partner leading the energy and material practice.

06:55 EDT Real Good Food launches crispy chicken shell tacos in WalmartWalmart - The Real Good Food Company announced the launch of its newest platform, crispy chicken shell tacos, in Walmart stores nationwide. Beginning today, consumers can find three varieties of crispy chicken shell tacos across approximately 3,500 Walmart stores nationwide.

06:52 EDT i-80 Gold acquires key water rights for Cove project - i-80 GOLD CORP announced that it has signed an Agreement to acquire a strategic property package located in Lander County, Nevada, that includes, among other things, 582 acre-feet of water rights, a rail heading on the Nevada Central Railway, several advanced-stage barite deposits, full barite processing infrastructure and known gold mineralized zones from Baker Hughes Oilfield Operations. This strategic acquisition provides i-80 with water rights for development and operation of the Cove open pit mine, marking a major milestone for executing on the Cove Project dewatering strategy. Highlights of the acquisition include: 582 acre-feet per annum of water rights to be used for the operation and eventual closure of the Cove Project; Barite processing facilities and associated infrastructure; A rail siding to provide the Company with access to the Northern Nevada Railway and property to be used or leased out for a variety of Commercial purposes; At closing, i-80 will own a 100% interest in the Property and associated infrastructure and assuming certain reclamation and related bonding liabilities on the Property. The US Geological Survey lists Barite as a "critical mineral" and the Company will complete a review of options related to mining and processing. McCoy-Cove is one of four projects currently being advanced for development and is expected to be a key project in the Company's plans to restart the Lone Tree autoclave. Construction of the decline at Cove is now underway with more than 300 ft advanced to date. This Phase 1 program will also include construction of an initial level with multiple drill bays to provide access for upgrading resources. Approximately 40,000 metres of underground definition and expansion drilling is anticipated to commence in H2-2022 followed by a Feasibility Study anticipated to be completed in 2023. The Cove deposit represents one of North America's highest grade gold deposits with grades in excess of 10 grams per tonne gold. The deposit remains open for expansion down-dip.

06:50 EDT Immuneering reaffirms FY22 operating expenses view $55.0M-$60.0M - Immuneering reiterates full year GAAP operating expenses to be between $55.0M-$60.0M including estimated non-cash stock-based compensation. Based on cash, cash equivalents and marketable securities as of March 31 the company expects its cash runway to extend into the Q3 of 2024.

06:49 EDT Pfizer to acquire Biohaven Pharmaceuticals for $148.50 per share - Pfizer (PFE) and Biohaven Pharmaceutical (BHVN) announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC ODT, a dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash. Biohaven common shareholders, including Pfizer, will also receive 0.5 of a share of New Biohaven, a new publicly traded company that will retain Biohaven's non-CGRP development stage pipeline compounds, per Biohaven common share. The boards of directors of both Biohaven and Pfizer have unanimously approved the transaction. Pfizer will pay transaction consideration totaling approximately $11.6B in cash. Pfizer will also make payments at closing to settle Biohaven's third party debt and for the redemption of all outstanding shares of Biohaven's redeemable preferred stock. The $148.50 cash consideration represents a premium of approximately 33% to Biohaven's volume weighted average selling price of $111.70 over the three months prior to the announcement of the transaction. This agreement follows on the November 9, 2021 collaboration for the commercialization of rimegepant and zavegepant outside the United States, in connection with which Pfizer invested $350M to acquire 2.6% of Biohaven's common stock at $173 per share. Following the closing, New Biohaven will continue to operate under the Biohaven name. New Biohaven will be led by Vlad Coric, MD, as Chairman and CEO, and include other members of the current management team of Biohaven. Biohaven common shareholders will receive, for each Biohaven share, 0.5 of a share of New Biohaven distributed via a pro rata distribution of SEC-registered, publicly listed shares. At distribution, New Biohaven will be capitalized with $275M of cash. New Biohaven will also have the right to receive tiered royalties from Pfizer on any annual net sales of rimegepant and zavegepant in the United States in excess of $5.25B. Pfizer expects to finance the transaction with existing cash on hand. Pfizer's acquisition of Biohaven is subject to the completion of the New Biohaven spin-off transaction and other customary closing conditions, including receipt of regulatory approvals and approval by Biohaven's shareholders. The companies expect the transaction to close by early 2023. Due to the proposed transaction, Biohaven will not hold a conference call to discuss its first quarter 2022 financial results and will issue a press release and file a quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission announcing those results on May 10, the companies noted.

06:41 EDT Immunic expects cash to fund operations into 3Q23 - Cash and Cash Equivalents as of March 31, 2022 were $95.7 million, which does not include the additional $10.0 million of net proceeds raised in April 2022 under the company's at-the-market sales agreement. As a result, current cash and cash equivalents are expected to fund Immunic into the third quarter of 2023.

06:40 EDT Immunic announces 2022 anticipated clinical milestones - Vidofludimus calcium in UC: Top-line data of the induction phase of the phase 2 CALDOSE-1 trial in patients with moderate-to-severe UC are expected to be available in June of 2022. IMU-935 phase 1 program in psoriasis patients: Recruitment of part C of the phase 1 clinical trial of IMU-935 in patients with moderate-to-severe psoriasis is ongoing in Australia and New Zealand. In addition, the part C portion of the trial has been submitted to authorities in Bulgaria and North Macedonia in order to expedite enrollment. Initial results from this third portion of the phase 1 clinical trial are expected to be available in the second half of 2022. IMU-935 phase 1 trial in mCRPC: Initial clinical safety data from the open-label phase 1 dose escalation trial are expected to be available in the third quarter of 2022. IMU-856 phase 1 program: The SAD part of the ongoing phase 1 clinical trial of IMU-856 has been completed. Based on the favorable data available, the Ethics Committee in Australia agreed to proceed to the MAD part which is currently being dosed. Unblinded safety data from the SAD and MAD parts in healthy human subjects are expected to be available in the third quarter of 2022.

06:36 EDT Everi Holdings board authorizes $150M share repurchase program - Everi's Board of Directors approved a new 18-month share repurchase program pursuant to which the Company may purchase up to $150 million of its common shares in open market or privately negotiated transactions through November 4, 2023 in accordance with Company and regulatory policies, and trading plans established in accordance with Rules 10b5-1 and 10b-18 of the Securities Exchange Act of 1934. The actual number of shares to be purchased will depend upon market conditions and is subject to available liquidity, general market and economic conditions, alternative uses for the capital and other factors. All shares purchased will be held in the Company's treasury for possible future use. As of March 31, 2022, Everi had approximately 91.5 million shares issued and outstanding, net of 25.7 million shares held in the Company's treasury. There is no minimum number of shares that the Company is required to repurchase, and the repurchase program may be suspended or discontinued at any time without prior notice. This new repurchase program supersedes and replaces in its entirety the previous share repurchase program.

06:30 EDT US Hybrid to launch natural gas-powered parallel hybrid powertrain hybrid tech - US Hybrid, a wholly-owned subsidiary of Ideanomics (NASDAQ: IDEX) and a leader in advanced battery, fuel cell, and hybrid electric vehicles, today announced the launch of near-zero-emission natural gas-powered parallel hybrid powertrain technology to be used for drayage and long-haul trucks. The new technology is currently on display at the ACT Expo in Long Beach, Calif., in Ideanomics' booth #1648. In conjunction with today's announcement, US Hybrid will host a press conference at ACT Expo at 2:15 p.m. PT. After six years of research, development, and rigorous testing, US Hybrid's new vehicle-agnostic technology will deliver more power, increased range, and a more efficient powertrain than diesel-powered engines or other CNG or renewable natural gas alternatives. The technological advantages include More Power: 640 hp combined power and 1770 lb-ft maximum torque from the natural gas-powered engine. The electric motor enables uphill acceleration with superior performance compared to its diesel engine alternatives. Less Fuel: A smaller 8.9 liters Near-Zero NOx engine will operate more efficiently, resulting in double fuel economy than a standard 15-liter engine and reducing fueling costs. Better Range: Preliminary testing suggests this fuel-efficient technology can deliver up to 1,000 miles of range per fuel fill, doubling range, power, and torque for similar CNG/RNG trucks. Increased Efficiency: The improvement in CNG engine performance paralleled with the electric motor, with appropriate controls, for transient load uptake results in lower NOx emissions and lower fuel consumption; Near-Zero-Emission: Our technology emits lower than 0.02 g/bhp-hr of nitrogen dioxide and will significantly improve the air quality of neighborhoods near ports and warehouses. Zero-Emission Port and Harbor Transportation Operations: Our technology delivers a lower HSE impact on port operations and the surrounding communities. This industry-first, advanced technology will add near-zero-emission road-side charging assistance to standard long-haul fleet operators, offering versatility and convenience to fleet customers.

06:18 EDT New Fortress Energy and Gasunie sign agreement to charter FSRU - New Fortress Energy announced that it has executed a binding agreement to charter a floating storage and regasification unit or FSRU, to N.V. Nederlandse Gasunie. The 5-year FSRU charter agreement will begin in Q3 2022 and provide storage and regasification capacity for Gasunie's new LNG import terminal in the port Eemshaven, the Netherlands. The Eems Energy Terminal will in total add approximately 8 bcm per year of new regasification capacity for NW Europe, with expected start-up in Q3 2022. This new terminal capacity will increase energy security for The Netherlands and create sufficient LNG import capacity to meet the country's gas needs without relying on pipeline imports, including gas from Russia. The binding FSRU charter agreement is subject to the execution of definitive documentation which is expected to be completed in the coming weeks.

06:11 EDT Diamond Offshore CEO says 'well situated for the repricing cycle' - Discussing the offshore drilling market, Mr. Wolford commented "We continue to see improvements in the moored, DP and drillship segments of the market. Rates and utilization for drillships have improved and are at recent cycle highs, and we expect this trend to continue in the coming months. The moored segment has also improved; however, it has been at a more measured pace and more geographically diverse than that of drillships. We are pleased to have significant backlog with repricing and new opportunities available to us in the quarters ahead. Customers continue to favor working rigs, and we believe Diamond Offshore is well situated for the repricing cycle currently under way in both the moored and drillship segments."

06:10 EDT Terran Orbital ships CAPSTONE satellite to New Zealand - Terran Orbital announced it has shipped its CAPSTONE satellite to a launch site on the Mahia Peninsula of New Zealand. CAPSTONE will launch on a Rocket Lab Electron rocket using a Lunar Photon satellite upper stage to send the spacecraft on its planned lunar transfer trajectory. This historic pathfinding mission supports NASA's Artemis program which includes landing the first woman and first person of color on the Moon.

06:04 EDT Aurinia sees FY22 revenue $115M-$135M from sales of LUPKYNIS - For FY22, the Company maintains its net revenue guidance of $115M-$135M from sales of LUPKYNIS. This range is based on assumptions regarding the impact of COVID-19 on the current business environment and represents an increase of more than 150 to 200% in net revenue from sales of LUPKYNIS compared to FY21. Aurinia's guidance does not include any potential milestone payments, royalties or contract manufacturing revenue related to the Company's licensing agreement with Otsuka Pharmaceutical or associated with the marketing of voclosporin in the European Union or Japan.

05:56 EDT Heinz, Pulpex to develop paper-based, renewable and recyclable bottle - Heinz is teaming up with Pulpex to develop a paper-based, renewable and recyclable bottle made from 100% sustainably sourced wood pulp. Innovating its iconic ketchup bottle, Heinz is the first sauce brand to test the potential of Pulpex's sustainable paper bottle packaging for its range of world-famous condiments. For The Kraft Heinz Company, this collaboration is the latest step in its journey to reduce its environmental footprint. It progresses the company's sustainable packaging ambitions, in that it aligns with its goal to make all packaging globally recyclable, reusable or compostable by 2025. It is also an innovation that will help Kraft Heinz achieve net zero greenhouse gas emissions by 2050.

05:52 EDT STMicroelectronics announces supply agreement with Semikron - STMicroelectronics has revealed it is supplying silicon carbide technology for the eMPack electric-vehicle power modules from Semikron, one of the world's leading manufacturers of power modules and systems. This is the result of a four-year technical collaboration between the two companies to design-in ST's advanced SiC power semiconductors for superior efficiency and industry-benchmark performance in more compact systems. SiC is quickly becoming the automotive industry's preferred power technology for EV traction drives, contributing to greater driving range and reliability. Semikron recently announced it had secured a billion-Euro contract to supply their innovative eMPack power modules to a major German car maker, beginning in 2025.